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Abstract
High-mobility group box 1 protein (HMGB1) is a nuclear component, but extracellularly 
it serves as a signaling molecule involved in acute and chronic inflammation, for 
example in sepsis and arthritis. The identification of HMGB1 inhibitors is therefore of 
significant experimental and clinical interest. We show that glycyrrhizin, a natural anti­
inflammatory and antiviral triterpene in clinical use, inhibits HMGB1 chemoattractant 
and mitogenic activities, and has a weak inhibitory effect on its intranuclear DNA 
binding function. NMR and fluorescence studies indicate that glycyrrhizin (and its 
analogue carbenoxolone) binds directly to HMGB1 {Kd ~ 150 |iM), interacting with two 
shallow concave surfaces formed by the two arms of both HMG boxes, altering the 
internal mobility of proteins (on the millisecond timescale for Box A, on the nanosecond 
timescale for Box B) without significantly altering their overall diffusive properties. Due 
to the reduced number of experimentally determined intermolecular contacts, by means 
of two different computational approaches (QRFF for the Box A - carbenoxolone 
complex, HADDOCK data driven docking for the glycyrrhizin containing complexes) it 
was possible to obtain an atomic level model of the protein-ligand interactions.
The presented results explain in part the anti-inflammatory properties of glycyrrhizin, 
and might direct the design of new derivatives with improved HMGB1-binding 
properties.
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List of Abbreviations, Acronyms and Definitions
CBNX Carbenoxolone
CNS Central nervous system
COPD Chronic Obstructive Pulmonary Disease
COX Cyclooxygenase
CPMD Carr-Parrinello Molecular Dynamics
5 Chemical shift
Dx y>z Diffusion tensor axis
DFT Density Functional Theory
FF Force Field
FL Full Length
fMLP formyl Met-Leu-Pro
FRAP Fluorescence Recovery After Photobleaching
GC Glucocorticoids
GL Glycyrrhizin
GR Glucocorticoid Receptors
HAC Histone Acetylase
HD AC Histone Deacetylase
hetNOE Heteronuclear Overhauser Effect
HMBC Heteronuclear Multiple Bond-Quantum Coherence
HMGB1 High Mobility Group B 1
HSQC Heteronuclear Single Quantum Coherence
IKK Ik Beta Kinase
IL Interleukin
J Spin-spin Coupling constant
LOX Lipooxigenase
MAPK Mitogen Activated Protein Kinase
MD Molecular Dynamics
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MM Molecular Mechanics
MMP Matrix Metalloprotease
NfkJB Nuclear Factor kB
NMR Nuclear Magnetic Resonance
NOE Nuclear Overhauser Enhancement
NOESY Nuclear Overhauser Enhancement Spectroscopy
NSAID Non Steroidal Antiinflammatory Drug
PLA Phospholipase
PME Particle Mesh Ewald
POPC Phosphatidylcholine
POPE Phosphatidylethanolamine
RMSD Root Mean Square Displacement
ROESY Rotating frame Spectroscopy
TNF Tumor Necrosis Factor
TOCSY Total Correlation Spectroscopy
RDC Residual Dipolar Couplings
SAID Steroidal Antiinflammatory Drug
SMC Smooth Muscle Cells
STD Saturation Transfer Difference
Tc Rotational correlation time
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t 2 Transversal relaxation time
TLR Toll-Like Receptor
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1. Introduction
1.1 Safer drugs, saving money: new routes to drug discovery.
Drug discovery is a process that covers different aspects of biomedical sciences, from 
basic knowledge to economical and marketing management, and that has a central role 
in the economic systems of all the richest countries worldwide: it is very long in terms of 
years of investment of human and economical resources as well. It has been estimated 
that the complete route that goes from a simple molecule to the pharmaceutical market 
covers approximately 15 years including in silico, in vitro and in vivo experimental 
procedures (http://www.hnnaeus.uu.se/online/pharm/lakemedelutveckling.html). Not all 
drugs have a successful life, that means that not all the molecules investigated by 
research centres and/or companies come to marketplace: during 1980 to 1992, the 
numbers of applications to investigate potential new drugs and numbers of new chemical 
entities approved each year by the FDA has remained flat at approximately 90 and 20, 
respectively (Kaitin et al., 1993). Economically speaking, current estimates for 
successful launch of a single new medication are in between US $300 million and US 
$800 million, nearly an order of magnitude higher than that for the NIH Molecular 
Libraries initiative for publicly available libraries (Di Masi et al., 1992; Rawlins, 2004).
In this century infant mortality and big infectious killers have been progressively 
replaced by cardiovascular diseases and cancer as the major causes of death. Decade 
upon decade, life expectancy has increased and, with it, the health care requirements of 
the elderly. A victim of the success of health care most broadly defined, the target for 
new pharmacological intervention has moved and is getting progressively more difficult 
to hit. In an analysis of 55 new chemical entities approved in the US in 1987 to 1989, 9 
(16%) were classified by the FDA as important therapeutic gain, 15 (27%) as modest 
gain and 29 (53%) as little or no gain (Kaitin et al., 1991). A repeat analysis covering 
1990 to 1992 found similar proportions (Kaitin et al., 1994). Therefore, in the last ten 
years in particular many drugs have been created as “me-too” drugs (Mason et al., 
1998), that are compounds that are very similar to already patented molecules but that
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have been slightly modified in order to avoid, e.g., side effects and because they 
represent safe markets. If this strategy avoided the investment of the great capitals that 
characterized the “Big Pharma” business between 70s and 80s, on the other side 
revealed a crisis within this world in terms of lack of novel scientific relevant 
discoveries in this field. Many problems must be faced during the drug discovery 
process, ranging from quantum chemistry studies of the molecules under investigation to 
the marketing strategies: the most relevant features of this process from a chemical and 
biological point of view are the the ability of being delivered in the organism (usually 
faced during the clinical phase I) and the evaluation of side effects. This last point 
should usually be covered during the phase III in principle (Di Masi et al., 1992), but 
they emerge during the market life of the drug and “me-too” drugs are designed in order 
to minimize the side effects of the original drug.
A way to avoid the great expense by pharmaceutical companies and to avoid any 
kind of problems with patenting is the usage of old drugs, originally designed with some 
purposes, for diseases that had not been considered in the past (Chong et al. 2007). The 
advantage of such an approach is both economic and pharmaceutical: the clinical trials 
can be largely or totally avoided, the side effects for old drugs are very well known and 
in many cases patents are no longer valid. In the last decade many drugs have been 
reused in the treatment of pathologies different than the ones for which they have 
originally been thought: for example, Nifepidine, originally designed to be a blood 
pressure control drug, has been successfully used for the treatment of hemochromatosis 
(Ludwiczek et al. 2007), or Astemizole was transferred from allergic rhinitis to malaria 
cure (Chong 2006). In particular, neurology and neurosciences are among the branches 
that gained major benefit from this strategy: Eritropoietin (EPO), a well known anemia 
drug (and sport dopant), has demonstrated its efficiency in protecting nerves from 
oxygen deficiency in brain ischemia (Lykissas et al., 2008). Also, multiple sclerosis and 
Huntington disease in the last year have obtained large benefits from the rediscovery of 
two drugs like, respectively, Atorvastatin (Li et al. 2007) and Clioquinol (Gouras et al., 
2001).
A family of drugs that are suitable for this rediscovery are anti-inflammatory
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drugs (Rhen et al., 2005; Rosen et al. 2005; Maroon et al., 2006): nowadays both 
steroidal and nonsteroidal drugs side effects are considered too risky for human diseases, 
hence some efforts have to be considered in order to create novel kinds of anti­
inflammatory drugs. Non steroidal anti-inflammatory drugs (NSAID) regulate the 
inhibition of the prostaglandine synthesis, being able to interact with both 
cyclooxygenase (COX) enzymes at the same time or with COX of type 2 only, whereas 
steroidal drugs (SAID) are able to interfere with NF-kappaB signalling that after 
activation is able to make the cells release cytokines and late mediators of inflammation. 
In both cases, side effects can be very dangerous or unhealthy: many cases of 
gastrointestinal, renal or vascular failures have been recorded in the recent past in 
patients treated with NSAIDs, whereas a high dosage of SAIDS induces inhibition of 
longitudinal growth in children, hypertension and osteoporosis in adults (van der Eerden, 
2003; Ullian et al., 1999). For these reasons, the ability of finding a new way of thinking 
to anti-inflammatory drugs is crucial for avoiding high risks in inflammatory diseases. 
Unfortunately, the possibility of ameliorating the modes of action of COX-related drugs 
is very low due to the differential expression of COX-1 and COX-2 and to their nature 
(see further): in this sense in the last years the majority of efforts have been focused on 
alternative drugs that could interfere with the NF-kappaB pathway or in the discovery of 
new inflammation pathways.
1.2 Steroidal and non steroidal anti-inflammatory drugs
The two most well estabilished ways of signalling inflammation are the glucocorticoid 
receptor (GR) way (Rhen et al, 2005; Maroon et al., 2006) and the ecosanoids 
production regulated by means of arachidonic acid pathway (Khanapure et al. 2007). 
The drugs that are involved in the blockage of the first pathway are chemically 
derivatives of cortisol and hence are called steroidal anti-inflammatory drugs (SAID) 
and are simply usually indicated as glucocorticoids (GC), whereas for blocking 
Arachidonic acid cascade drugs that are able to inhibit the activity cyclooxygenase 1 and 
2 (COX1 and COX2) are used that are called, due to their chemical nature, non-steroidal 
anti-inflammatory drugs (NSAID). In the two following subsections, the modes of action
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of these two distinct types of drugs are highlighted together with a sketch of the 
biochemical mechanism in which they are involved.
1.2.1 Glucocorticoids
Glucocorticoids are a class of steroid hormones originally identified to be crucial in 
controlling the blood glucose content, from which the name derived. Glucocorticoids 
must be distinguished from mineralocorticoids and sex steroids mainly because of 
receptors involved in their biochemistry and/or cells type involved. The glucocorticoid 
receptor (GR) is a member of the steroid-hormone-receptor proteins family (Breuner et 
al., 2002), it is expressed almost in all type of cells, and its expression is mainly 
regulated by proinflammatory agents tumor necrosis factor (TNF) alpha and interleukin 
(IL) 1. Its endogenous ligand is cortisol, which is secreted by adrenal cortex and 
converted to cortisone by 11 p-hydroxysteroid dehydrogenase II (Sahia, 2008) in 
response to neural, cytokine and endocrine stimuli (see Fig. 1.1a). Three different modes 
of action have been identified for cortisol (Fig. 1.2): i. the complex formed by cortisol 
and GR is recruited by the nucleus for activating gene expression directly interacting 
with DNA in a sequence specific fashion (GR responsive elements); ii. no direct 
interaction between DNA and cortisol-receptor occurs, but the interaction is mediated by 
various nuclear factors (see further) that are able to regulate gene expression; iii. other 
membrane receptors are activated by the formation of ligand-receptor complex (non 
genomic pathway). Both in the genomic and in the non-genomic ways phosphorylation 
is the most relevant posttranslational modification that is performed by Mitogen 
Activated Protein Kinase (MAPK) mainly in a ligand dependent manner (Ismaili et al., 
2004): GR is also frequently ubiquitinated and sumoilated for targeting proteosomal 
degradation (Holmstroon et al. 2003; Le Drean et al. 2002). The anti-inflammatory 
activity of cortisol and derivatives is mainly related to the inhibition of the biosynthesis 
of eicosanoids: this process is controlled by the activation of Annexin I and of MAPK 
phosphatase 1, and by the downregualation of genes that control the expression level of 
cyclooxygenase 2. Annexin I is an anti-inflammatory protein that interacts directly with 
PLA2, the enzyme that converts the membrane phospholipids into arachidonic acid
7
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Fig. 1.1. a. Cortisol-cortison interconvertion through an oxidoreduction reaction b. aspirin (acetyl salycilic 
acid) molecule; c. celecoxib (commercial name: Celebrex) molecule.
(Kim et al., 2001) maintaining the membrane haemostatic balance unaltered; the 
formation of Annexin I -  PLA2 complex is then able to block the release of arachidonic 
acid. MAPK phosphatase 1 is the protein that controlsth the activation of all the 
members of MAPK proteins family and of Jun N terminal kinase, hence it’s 
expression/activation is able to inactivate the kinase cascade that is necessary for 
controlling the enzymatic activity of PLA2 and also to block the phosphorylation of 
PLA2 itself (Gjion et al.1999). If the above mentioned anti-inflammatory therapy is 
really efficient and rapid, there are many disadvantages that have to be considered with 
care (Schacke et al., 2002): hypertension is one of the most evident cortisol and cortisol- 
derivative side effects, and also wound repair is in some extent inhibited due to the
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Fig. 1.2 G lucocorticoid pathw ays during response to inflam m ation (from  Rhen et al, 2005).
downregulation of genes that control the expression level of collagen and matrix 
metalloproteases (MMPs). Moreover, in children a GC based therapy would have 
detrimental effect on growth, whereas in elderly people a serious problem facing with 
osteoporosis has been detected up to date.
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1.2.2 Prostaglandins, COX-1, COX-2 and the mode o f action ofNSAIDs 
Traumatic, chemical or autoimmune tissue injury put any type of cells in condition to 
release short-lived and localized hormones that can induce inflammation, pain, fever 
once they have been translocated to extracellular matrix and then they are able to 
interact with respective receptors: these molecules are called prostaglandins (Khanapure 
et al. 2007). They are the most abundant member of eicosanoids, small molecules all 
involved in inflammatory processes at different extent, so named because of the 
chemical origin from the 20 carbon atoms that form the backbone of 
arachidonic/prostanoic acid (Fig. 1.3a): the biological activity of ecoisanoids is various 
and can be both favourable and unfavourable, ranging from, e.g., checking ordinary 
functions in the gastrointestinal tract to amplifying pain or restricting vessels diameter 
during inflammation. Together with prostaglandins, the family of eicosanoids is also 
composed by thromboxanes , that are exclusively involved in the coagulation cascade, 
and by leukotrienes, involved in cells stimulation for enhancing the production of 
interleukins and interferons during inflammatory process and are of central importance 
in autoimmune diseases (Dharmananda, 2003; Funk, 2001).
The pathway that brings to the synthesis of prostaglandins starts from the cell 
membrane: after injury Phospholipase 2 (PLA2) recruits phosphatidylethanolamine 
(POPE) and phosphatidylcoline (POPC) and converts them into Arachidonic acid, which 
is then converted into eicosainoids by the enzymes lipooxygenase (LOX) and 
cyclooxygenase (COX): the former produces leukotrienes, the latter thromboxanes and 
prostaglandins (Fig. 1.3b). Between 60s and 70s John Vane and his coworkers were able 
to find a link between an anti-inflammatory drug of longstanding tradition like aspirin (it 
was synthesized in 1875, Fig. 1.1b), cyclooxygenases and prostaglandins (Vane, 2003): 
aspirin is able to inhibit the enzymatic activity of COX, hence decreasing the production 
of proinflammatory eicosanoids and reducing inflammation, pain, fever and blood 
clotting. Due to the different chemical nature of aspirin (acetylsalicylic acid) with 
respect to steroidal drugs, aspirin and its derivatives were called non steroidal 
antiinflammaotry drugs (NSAID): the same name was adopted for drugs that did not 
display chemically a cortisol-like structure. 20 years later two active forms of
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cyclooxygenase were discovered and named COX-1 and COX-2 (Vane et al., 1995).
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Fig. 1.3 a. Arachidonic acid; b. COX-1 and COX-2 pathways during inflammation (from Maroon et al., 
2005).
COX-1 is constitutively expressed almost in all cells and it has a role in balancing 
homoeostasis and in protecting intestinal mucosa (Seibert et al., 1994), whereas COX-2 
is expressed only in cells that are involved in inflammation (Moncado et al., 1976): 
therefore, COX-2 is the only cyclooxygenase responsible for mediating inflammatory 
response in cells. The mode of action of aspirin had been already explained by Vain in
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70s, but there was no clue for gastrointestinal side effects: with the discovery of COX2 
and the comprehension of the cellular and tissue localization of both COXs it was 
evident that only selectively blocking COX2 was possible to avoid side effects of 
aspirin, hence a new class of drugs that could selectively inhibit COX2 was the new goal 
of pharmaceutical industry at the beginning of 90s. This led in 1998 to the approval of 
celecoxib (Fig. 1.1c) by FDA for the treatement of arthritis (Clemett et al., 2000), and 
within some moths other two drugs of this kind (rofecoxib and valdecoxib) were 
approved and in some months the three (jergally named “The Big Three”) became 
pharmaceutical market leaders among anti-inflammatory drugs and among drugs in 
general, leading, e.g., to about 20 million people in US only using selective COX2 
inhibitors for medium and long term usage as anti-inflammatory therapy (Maroon et al., 
2008). In 2004 the APPROVe study (Hegmann, 2005) lead by the Merck Research 
Laboratories indicated that after 18 months of usage of rofecoxib (commercially 
Merck’s Vioxx) many patients manifested some kinds of thrombolytic events, even 
myocardial infarction in the most dramatic cases, and the percentage of risk was even 
higher in patients with a basal high risk (Caldwell et al., 2006). The reason of this side 
effect was the breaking of the equilibrium between the unchanged production of 
thromboxanes by COX-1 in platelets and the inhibition of the production of 
prostacyclins by COX-2 : the former are thrombogenic, the latter are thrombolitic, hence 
selective COX-2 inhibitors lead to an increase percentage of risk of thrombolitic events. 
This, together with other similar studies, withdrew the usage of such drugs and pushed 
towards the research of novel roads for drug discovery in the field of inflammation and 
of anti-inflammatory drugs.
1.3 NF-kappaB based inflammation pathways
In the light of the problems presented by both steroidal and nonsteroidal drugs and listed 
in the previous section, many efforts have been done since 80s in order to discover new 
pathways that could lead to the design of novel anti-inflammatory drugs. The most 
promising one was the NF-kappaB pathway, that pushed towards a nuclear view of 
inflammation with respect to antiCOX based herapies: NF-kappaB has been extensively
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studied since mid 80s (Gilmore et al., 1986) and more strongly related to inflammation 
and oxidative stress at the beginning of 90s (Bonizzi et al., 2004), and this field of 
research revealed suddenly its importance in oncology due to the strong relationship 
between certain types of cancer and inflammation with NF-kappaB acting as a bridge 
between two apparently distinct pathologies.
In practice no efforts have been done in order to design new drugs that could 
interfere directly with the NF-kappaB pathway because of the very poor way of 
controlling the fate of such a drug in expressing or silencing unwanted genes in the 
complex regulatory network. Nevertheless, since 90s many efforts have been done to 
clarify the effect of natural drugs or existing synthetic drugs originally designed for 
other purposes on the NF-kappaB pathway in order to understand the possibility of 
interfering with the inflammation process. The advantage of using natural compounds 
that are present in common foods is to have diet integrators that could be helpful in some 
specific situation (i.e., athletes suffering inflammation, high sensibility to drugs) 
(Maroon et al., 2006) ; the rediscovery of old drugs is extremely advantageous from both 
an economical point of view and an experimental point of view due to the possibility of 
avoid clinical phases for monitoring side effects (drugs of long-standing tradition have 
been already tested and monitored).
In the following subsections NF-kappaB will be introduced in more details, giving some 
basics of its interactions and its networking among different genes; afterwards, both 
some natural drugs (curcumin, catechins and resveratrol) and the modes of action of old 
“recycled” commercial drugs (thalidomide) within the NF-kappaB pathway will be 
shown.
1.3.1 The NF-kappaB pathway, a nuclear weapon towards inflammation 
A  search of publications indexed for Medline and concerning NF-kappaB reveals that 
there are approximately 23000 papers published and almost 10 % of them are reviews 
about it, indicating that maybe NF-kappaB is the most studied proteins worldwide. Its 
popularity derives from the discoveries in the first half of 80s of three proteins that 
displayed a great variability in subcellular localization and in shuttling between the
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cytoplasm and the nucleus (Gilmore, 1990): these three proteins had been named NF- 
kappaB, v-Rel and Dorsal and despite the same kind of subcellular localization they 
were involved respectively in immunity, oncogenesis and development (Karin, 2006) . 
In the following years it became clear that apart from the involvement in different 
tissues and systems the three proteins belonged to the same large family of proteins that 
are nowadays almost always referred as NF-kappaB, maybe because it is the protein to 
which more effort has been dedicated in these years and because the immunological 
studies were the ones that provided more physiologically relevant information about this 
system (Hayden et al., 2008).
NF-kappaB family of proteins (Perkins, 2007) is divided into two subfamilies, 
the NF-kappaB and the Rel subfamilies: the former contains three elements (plOO and 
p i05, plus Relish in Drosophila) and the latter five (RelA, RelB and c-Rel, plus Dorsal 
and Dif in Drosophila). A common feature between these two subfamilies is the 
presence of a Rel homology domain (RHD) (Gilmore, 1990) that can serve both as a 
DNA binding and a dimerization domain. Proteins belonging to REL subfamily have a C 
terminus transactivation domain (TAD) that is responsible for the positive regulation of 
genes and that displays high variability allowing the regulation of many different genes 
(see further). NF-kappaB subfamily proteins usually are not transcription factors: 
however, they present at the C terminus ankyrin repeats that regulate the interaction with 
other proteins, therefore they can act as transcription factors when they form 
heterodimers with Rel subfamily proteins (Chen et al., 1999). In this last case the protein 
is subjected to limited proteolysis (p i05 and p i00 are respectively transformed into p50 
and p52) ankyrin repeats are able to block the transcriptional activity of THDs (Hayden 
et al., 2004). Among these dimers the most relevant and most frequently studied is p50/ 
Rel-A, also known as p50/p65 dimer and very often referred as NF-kappaB itself. The 
activity of NF-kappaB as a transcription factor is regulated by Ik-B cytosolic proteins 
that form complexes with NF-kappaB: according to structural studies, IkB and NF- 
kappaB are in close contact burying nuclear localization signal of Rel, whereas the one 
of p50 is left exposed, ensuring a fine control on the shuttling of an inactive form of 
complex from the cytosol into the nucleus and vice versa, avoiding unwanted gene
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expression. The complex is transiently activated by IkB kinase (IKK) that phosphorilates 
IkB (Hayden et al., 2004) and leads to its proteosomal degradation and to the shuttling of 
p50/p65 complex into the nucleus, and hence to gene expression through its interaction 
with 9-10 base pairs DNA sites (kB sites) (Gilmore, 2006). This NF-kappaB signal 
transduction pathway is called canonical pathway (Hayden et al., 2008); other 
mechanisms have been identified {i.e., non canonical pathway fo T cells activation) or 
are under investigation (Perkins, 2006). The three mechanisms are reported 
schematically in Fig. 1.4.
1.3.2 Natural drugs against NF-kappaB
Due to the long term tradition behind them and to the spread usage of them, natural 
drugs are compounds whose primary and side effects are very well known and 
documented. Beside a knowledge provided by popular medicine, more recently these 
molecules have been investigated adopting contemporary scientific standards in order to 
provide detailed information about their biochemistry and their molecular biology 
activity (Maroon et al, 2006).
In this sense in the last decade there has been an intense research activity that led to an 
increased interest towards common plant derived compunds like polyphenols (Feng, 
2006). Polyphenols are the principal constituents of green tea, a dietary supplement 
whose preventive effects towards cardiovascular diseases and cancer has been widely 
recognized in the last years and attributed to its antioxidant properties. In particular, 
main efforts have focused on the study of Epigallocatechin-3-Gallate (EGCG), the most 
abundant catechin of green tea (Kundu et al., 2005) (Fig. 1.5a). Several recent studies 
demonstrated that the inactivation of NF-kappaB by EGCG was associated with 
inhibition of IKK activity (Chen et al., 2002), enhancement of phosphorylation 
dependent degradation of I B and subsequent increase in nuclear translocation of p65 
protein (Wheeler et al., 2004). In this sense it has been also recently suggested that 
EGCG could partially inhibit in epithelial cells, through the interaction with the NF- 
kappaB pathways, the release of IL-8, a primary neutrophils attractant during the
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Fig. 1.4 NFKB pathw ays a. canonical pathw ays (see text); b. non canonical pathw ay: it islargelyconnected 
to the activation o f  plOO/RelB com plexes during B-and T-cell organ developm ent, and it differs from the 
canonical pathw ay in that only certain receptor signals (e.g., B-cell activating factor or CD 40) activate 
this pathw ay and because it proceeds through an IK K  com plex that contains tw o IK K a subunits ; c. new 
non canonical pathway: p50 (or p52) hom odim ers enter the nucleus, where they becom e transcriptional 
activators by virtue o f interaction with the IkB -like co-activator Bcl-3 (or IkBz). How Pathw ay 3 is 
regulated is not known (from G ilm ore, 2006).
inflammation process. Another study proposed also a T cells specific effect of ECGC in 
downregulating NF-kappaB: the drug is able to inhibit the catalytic activity of both 20S 
and 26S proteasome, as demonstrated in vitro , thus leading to an accumulation of 
intracellular IkB and to an inhibition of NF-kappaB activation . This has the 
consequence of blocking TNF alpha synthesis and to induce T cells cycle arrest, 
preventing any autoimmune response (Aktas et al., 2004).
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Fig. 1.5 a. EGCG molecule b. curcumin molecule.
Curcumin (difeluroyl methane, Fig. 1.5b) is another compound that capitalized the 
experimental efforts of many pharmaceutical chemists and molecular biologists, as 
shown by recent publications in this field of research (Kundu et al., 2005). This 
molecule is the major component of many spices that are mainly members of the ginger 
family, among which curry is the most diffused one, especially after its introduction in 
western countries by means of the diffusion of Indian and Chinese food. The relevance 
of curcumin in biological processes has been already understood by ayurvedic medicine 
(I.e, the Indian traditional medicine) that makes large usage of curcumin for the topical 
treatment of skin wounds, herpes zoster, acne and parasitic skin infections (Strimpakos
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et al., 2008). During 80s curcumin has been quite extensively biochemically studied and 
the antioxidant ability of the drug emerged rapidly from many studies (Strimpakos et al., 
2008). Moreover, many evidences emerged from experiments performed on human 
platelets, colon epithelial cells and rat peritoneal neutrophils that indicated in curcumin 
an antiinflammatory drug that was able to interact with the pathway arachidonic acid 
through inhibition of COX-2 gene expression, thus acting at more nuclear level than 
synthetic COX-2 inhibitors (Plummer et al., 1999). More recently, however, it became 
more evident in the last five years that also the NF-kappaB pathway is influenced by the 
assumption of curcumin: in late 90s already a role for curcumin in NF-kappaB pathway 
has emerged in bone marrow stromal cells through TNF-a induced activation of NF- 
kappaB transcription (Kim et al., 2007), in agreement with the observation that in colon 
cells curcumin is able to inhibit the formation of the NIK/IKK signaling complex at the 
level of IKKa/IKKb dimer (Plummer et al., 1999), thus being able to prevent the 
overexpression of COX-2 especially in colon cancer. These latest discoveries allowed 
the approval of an experimental protocol for phase II chemopreventive trials for the 
treatements of patients with colon cancer with curcumin (Murakami et al., 2007).
1.3.4 Rediscovery o f old drugs as NF-kappaB inter actors
Natural drugs are very promising molecules for some diseases, as they can be easily 
integrated in normal diet and in some cases they can be used at high doses in clinical 
trials. However, clinical trials are very expensive, and only in the last twenty years 
natural substances are going to be reconsidered for their pharmaceutical relevant 
properties, due to the lack of real scientific information about their activity, as explained 
in the above section. In this sense, one of the latest discovery activity of pharmaceutical 
companies is the rediscovery of old drugs for diseases that have not been considered as 
their original targets. This procedure is very cheap because the clinical trials for these 
drugs have already been performed and for many of them side effects and posology are 
very well known. In some cases also long term side effects, i.e. the ones that have not 
been covered during clinical trials but only after huge usage by customers during the 
market life of the drug, are known and very well documented with a reliable statistical
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relevance. In this sense, in the last decade NF-kappaB seems to be the most relevant 
target of this branch of research for what concerns inflammation and antiinflammatory 
drugs, due to the dangerous side effects of COX-2 selective drugs and due to the 
aforementioned problems about inhibition of prostaglandines synthesis.
The most relevant and recent example of this rediscovered drugs is thalidomide. This 
compund ([+]-a-phthalimidoglutarimide, Fig. 1.6a) was first synthesized almost 50 years 
ago as an antihistamine drug (Raje et al., 2002) and soon found to have sedative effects 
in animal studies. Due to lack of toxicity in animals at high doses, it was approved in 
1957 as an over-the-counter sedative during pregnancy in almost 50 countries. Flowever, 
this success did not last very long, because thalidomide was found to induce birth 
defects in humans; it was withdrawn from the market in 1965 (Meierhofer et al., 2001). 
About thirty years later thalidomide selective inhibition of TNF produced by stimulated 
human monocytes was demonstrated, and the central role of TNF in a wide variety of 
diseases placed this drug on a comeback trail (Ogata et al., 2003). In 1998, thalidomide 
was approved in the United States for the treatment of erythema nodosum leprosum, a 
complication associated with leprosy (Richardson et al., 2002).
In 1999 (Moreira et al., 1999) a decrease in endothelial cell proliferation in 
cultures treated with thalidomide or the thalidomide analogue cc-1069 was observed, 
The inhibition occurred in association with a marked decrease in the activity of the 
nuclear factor SP1 and a moderate inhibition of NF-kappaB activation in nuclear 
extracts of endothelial cells. These findings indicated that thalidomide and analogs could 
have anti-inflammatory, antiangiogenic and immunomodulatory properties. In the 
following years several papers were published that demonstrated the NF-kappaB 
inhibitory properties of thalidomide (Jin et al., 2002): this drug is able to inhibit the NF- 
kappaB associated release of IL-lp in colon cancer cells and, more in general, NF- 
kappaB activation is suppressed by thalidomide in different ways that depend on the 
proinflammatory stimulus used on cell cultures {i.e., TNF and hydrogen peroxide 
stiumulation of NF-kappaB is inhibited by thalidomide, whereas no effect is observed if 
ceramide, phorbol esther or lipopolisaccharides are used). More recently, also in burn
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injuries TNF levels appeared to be decreased by thalidomide (Eski et al., 2008). Due to 
the relevance of the NF-kappaB pathway on the multiple myeloma pathology in these 
last years, thalidomide has been experimentally investigated as a potential anti myeloma 
agent, demonstrating a potential antiapoptotic effect of this drug among others tested 
(Mitsiades et al., 2002).
Fig. 1.6 a. Thalidomide molecule b. Theophilline molecule.
1.4 Looking for antiinflammatory targets: what's new
If all the above listed drugs could be a good choice for some alternatives to the usage of
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more “standard” drugs in a near future and, in the case of natural drugs, a good way for 
preventing the degeneracy or even the appearance of inflammatory events, a question 
still remains open. Are there any other way to block inflammation finding genetic or 
biochemical pathways alternative to the ones historically targeted for anti-inflammatory 
purposes? In a more practical way, could it be any possibility of finding a novel protein 
target in order to elaborate a new and robust anti-inflammatory strategy? In this sense, 
very recently three proteins have been identified to be good candidate for modulating 
inflammatory response in the organism: histone deacetylases (HDACs), Interleukin 33 
(IL33) and extracellular High Mobility Group Box 1 (HMGB1) protein, which is the 
object of the present work.
1.4.1 Theophyllin and HDACs
At nuclear level and within the process of chromatin remodeling, acetylation of core 
histones is a mechanism associated with activation and transcription of various genes 
and is regulated by coactivator molecules (HAC) that have intrinsic histone 
acetyltransferase activity (Urnov et al., 2001). Also some genes that express proteins 
involved in inflammation are regulated by acetylation: proinflammatory transcription 
factors such as NF-kappaB bind to coactivator molecules and activate this enzyme. 
Histone acetylation is reversed by HDACs: decreased HD AC activity also results in 
increased NF-kappaB mediated inflammatory gene expression without affecting NF- 
kappaB DNA binding (Ichiyama et al., 2001). This process is deeply studied since 20 
years as a basic chromatin remodeling process, but its role in inflammation in 
inflammation only emerged in the last years. However, no drugs seemed to be involved 
in any interaction with H AC/HD AC pathway.
Theophylline (Fig. 1,6b) is one of the most widely used drugs in the treatment of 
COPD (chronic obstructive pulmonary disease) since 1940s, and recently published 
guidelines for COPD recommend theophylline as one of the central drugs in the 
management of symptomatic COPD, despite the preference for inhaled P-agonists 
especially in the richest countries for some unavoidable side effects of theophylline. The 
mode of action of this drug remained unexplored and unclear for many years. A partial
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Fig. 1.7 Theophylline directly activates histone deacetylases (FIDACs), w hich deacetylate core histones 
that have been acetylated by the histone acetyltransferase (H AT) activity o f coactivators such as CBP 
(cA M P-responsive elem ent-binding [CREB] protein). This results in suppression o f  inflam m atory genes 
and proteins, such as granulocyte-m acrophage colony- stim ulating factor (G M -C SF) and interleukin 
(IL)-8, that have been sw itched on by proinflam m atory transcription factors, such as NF-B. 
C orticosteroids also activate H D A C s but through a different m echanism , resulting in the recruitm ent o f 
H D A Cs to the activated transcriptional com plex via activation o f the glucocorticoid receptors (GRs), 
which function as a m olecular bridge. This predicts that theophylline and corticosteroids may have a 
synergistic effect in repressing inflam m atory gene expression (from  B arnes, 2005).
antiinflammatory effect was already carachterized starting from the end of 90s and 
related to the NF-kappaB mediated expression of IL-8, but this effect was only observed 
in cells at low concentration of theophylline (Tomita et al., 1999).
Very recently, some publications revealed that in COPD NF-kappaB activation is 
increased in macrophages in induced sputum, peripheral lung and airway epithelial cells; 
moreover, there is a m arked reduction in HDAC activity in COPD alveolar 
macrophages, bronchi, and peripheral lung (Di Stefano et al., 2002) and decreased 
HDAC activity also results in increased NF-kappaB mediated inflammatory gene 
expression without affecting NF-kappaB DNA binding (Zhong et al., 2002). 
Corticosteroids suppress the expression of inflammatory genes by binding to and
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activating glucocorticoid receptors, which recruit HDAC2 to the transcription complex 
of inflammatory genes that is activated, thereby reversing histone acetylation and 
silencing genes that have been activated by inflammatory stimuli (Ito et al., 2000). These 
mechanisms appear to account for most of the antiinflammatory effects of 
corticosteroids in asthma: however, in COPD the marked reduction in HDAC activity 
and expression may account for the characteristic resistance to the antiinflammatory 
effects of steroids seen in this disease (Barnes et al., 2004).
Theophylline activates HDAC activity and therefore suppresses the expression of 
inflammatory genes (Ito et al., 2002a) (Fig. 1.7) It is not yet certain whether HDACs are 
the direct target of Theophylline, because several other nuclear proteins are 
coprecipitated in these inflammatory gene complexes. Theophylline activates different 
subtypes of HDAC, with equal activation of HDAC1 and HDAC2 (Ito et al., 2002b).
The mechanism whereby low concentrations of theophylline activate HDAC is not yet 
known. The effect of theophylline on HDAC activity appears to be potentiated under 
conditions of oxidative stress. In the sense of a rediscovery of old or traditional drugs, 
the aforementioned novel possible usage of Theophylline is illuminating for two 
reasons: 1. a new mechanism has been identified that switches gene regulation at 
molecular level but with a different mechanism with respect to the most studied process 
that involves NF-kappaB; 2. an old drug that has been (and still it is) used for a purpose 
(i.e., bronchodilation) in this new context finds a new role as an antiinflammatory drug. 
However, despite the promising features, major problems in adopting theophilline as a 
new antinflammatory drug are the side effects of Theophylline has. Moreover, histone 
acetylation/deacetylation is a very delicate biochemical process, hence interacting 
directly with it could be very dangerous for the cell cycle and gene expression. Hence, if 
on one hand this is a possible route for saving money and have a ready to go drug, some 
severe questions are still open, and new targets are worth to be investigated and many 
other data must be collected in the near future.
1.4.2 IL33 boosting
In 2005 a paper published by the journal Immunity reported evidences that IL-33, an
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interleukin belonging to the family of IL-1, is able to bind to IL-1 receptor ST2 on the 
surface of T Helper cells and hence to induce the release of proinflammatory cytokines 
from stimulated cells (Schmitz et al., 2005). In mid 90s two different peptidic ligands 
were discovered (Kumar et al., 1995; Gayle et al., 1996), but they did not belong to the 
interleukin family and did not display any biological, activity, as they were not able to 
activate NF-kappaB pathway. IL-33, instead, was demonstrated, both in vitro and in 
vivo, to both directly bind ST2 and to activate NF-kappaB pathway through 
phosphorylation and MAP kinases in mast cells. This is reflected in the production of 
cytokines by T helper cells, and anatomical changes were observed in the lung and in the 
digestive tract in mice. In the following years, there have been many efforts in the 
direction of providing a more detailed description of the IL33-ST2 interaction and of its 
pathological and physiological relevance because of the influence of this complex on 
inflammatory processes in cells. In this sense, also the chemoattractant activity of IL-33 
towards T helper cells has been demonstrated and evidences have been found of the 
IL-33 stimulation of cytokines release also by mast cells. IL-33 is involved at least in 
three different pathologically relevant mechanisms: IL33-ST2 interaction has bee 
detected in vivo in animal models (murine thymoma cell line) of airway inflammation 
and the same release of cytokines previously described has been observed; b. in cardiac 
heart cells IL-33/ST2 signaling is biomechanically (due to the mechanical contact 
between cardiac fibroblasts and cardiomyocytes) activated and it controls the 
cardiomyocyte hypertrophy and cardiac fibrosis; c. IL-33 has a role in atherosclerosis 
prevention because it is able to induce in high fat diet mice the production of antibodies 
against IL-5 and oxidized LDL, hence preventing the formation of typical 
atherosclerotic plaques in vessels.
From a molecular point of view, IL-33 is a dual function endothelium derived 
protein that may function as both a proinflammatory cytokine and an intracellular 
nuclear factor with transcriptional regulatory properties: IL-33 is identical to NF-HEV, a 
nuclear factor preferentially expressed in high endothelial venules (HEV), it is a 
heterochromatin-associated nuclear factor in HEV endothelial cells in vivo and it possess 
transcriptional repressor properties, associated with the homeodomain-like helix-turn-
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helix motif. All these features, taken together, demonstrate that IL-33 and its interactions 
with its receptor ST2 could become central in the development of an antiinflammatory 
drug in the next future. However, up to date, no information about IL-33 structure are 
available nor an atomic level description of interactions between IL-33 and ST-2, which 
are the necessary prerequisites for drug discovery and/or design.
1.5 HMGB1: from nucleus to outside the cells triggering inflammation
1.5.1 HMGB1 and the nucleus: a story o f long ago
Like IL-33, also HMGB1 has the dual role of architectural chromatin binding protein 
and of cytokine, making HMGB1 a possible interesting target for drug discovery. 
HMGB1 was initially discovered almost 30 years ago and in early stages of research it 
was named amphoterin. It was readily identified as an abundant (up to a milion 
molecules per cell, almost 10% of the population of nuclear histones) nuclear protein 
(expressed in mammals, yeast, bacteria and plants) that is important for the regulation of 
gene transcription and for chromatin remodeling and architecture (Rauvala, 2007). The 
human gene of HMGB1 is located on chromosome 13ql2 and encodes 216 residues 
divided into two domains named Box A and Box B, approximately of 70 residues each, 
and a 30 residues acidic tail that, in the protein in its resting state, interacts with basic 
stretches in Box A and B, shielding them from other interactions that might occur before 
HMGB1 binds DNA (Fig. 1.8). The knockout mouse of HMGB1 is lethal, although 
HMGB2 and HMGB 3 molecules can provide redundancy during embryogenesis 
(Calogero et al., 1999) . However, HMGB1 binds rather weakly to the B-form variety of 
DNA, and has practically no sequence specificity. Instead, it binds with high affinity to 
unusual DNA structures like 4-way junctions and DNA bulges; this suggested that 
HMGB 1 might actually function by distorting linear DNA into a bent conformation. The 
considerable energy required for DNA bending comes from the extensive contacts of 
HMG boxes within the minor groove of DNA. LEF-1 and SRY - transcription factors 
that incorporate an HMG Boxes - also bend DNA as part of their activity; the difference 
in sequence specificity between LEF/SRY and HMGBs has now been traced to specific 
amino acid residues (Lotze et al., 2005) .
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Obviously, HMGB1 will interact in the nucleus with distorted DNA structures, 
such as those created by the incorporation of nucleotide analogues, by covalent 
modification or by adducts formed upon UV irradiation (Agresti et al., 2003) . HMGB1 
shields cisplatin-damaged DNA from repair processes (He et al., 2000). Important as 
they are, these functions do not justify the abundance of HMGB1; whether HMGB1 is 
involved in homologous recombination is still undecided, although it can promote the 
non homologous integration of exogenous DNA into the genome (Ueda et al., 2002) . 
HMGB1 causes DNA bending and facilitates the binding of several regulatory protein 
complexes to DNA, particularly members of the nuclear hormone-receptor family, 
V(D)J recombinases and p53-p73 transcriptional complexes. HMGB1 overexpression, 
which is observed in many tumor cells, accelerates cell-cycle progression, presumably 
through its ability to promote access to some (and not other) transcriptional complexes. 
Interestingly, in some tumor cells, HMGB1 can be polyADP-ribosylated, a common 
phenotype change in proteins present in cells with damaged DNA associated with the 
invasiveness of tumors. HMGB1, similar to the functionally related bacteriophage 
proteins IHF and HU, stabilizes nucleoprotein complexes simply by its capacity to 
maintain a bend in DNA. Indeed, HMGB1 and members of the HMG domain protein 
family have unusual relationships with viruses: in some cases, they inhibit viral 
integration into the genome by binding viral DNA; and in other cases, they are targets 
for early viral inactivation (Lotze et al., 2005).
HMGB1 is very mobile within the nucleus, being able to traverse the entire 
compartement in less than 2 seconds due to a very transient association to chromatin 
associated to a jumping mode of binding of HMGB 1 to different nucleosomes.
1.5.2 From nucleus to outside
HMGB1 does not contain any signaling sequence, hence it can not pass through 
endoplasmic reticulum or Golgi apparatus. However, secretion (or active release) of 
HMGB1 has been observed in many types of cells like macrophages, monocytes, 
neutrophils, platelets, dendritic cells and NK cells stimulated with LPS or with 
proinflammatory cytokines like TNF, IL-1 (3 or IFNy. This is a rare but not uncommon
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event, since also other proteins (e.g., IL -lb  and FGF) are released without displaying a 
consensus sequence (Yang et al., 2005). Being independent from common secretory 
pathway, active release of HMGB 1 depends on the relocalization from the nucleus to 
special organelles, the secretory lysosomes (Bonaldi et al., 2003). M oreover, it has been 
demonstrated that HMGB1 is relocated from nucleus through cytosol after acetylation 
induced by LPS or, in resting macrophages, by acetylases hyperacetylation (Bonaldi et 
al., 2003). In addition to active release, monocytes and macrophages are able to
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Fig. 1.8 HM GB1 structure and organization a. schem atic representation o f HM GB1 (from  Yang et al. 
2005); b. structure of the Box A o f  H M GB 1; c. structure o f  the Box B o f HM GB 1.
passively secrete HMGB1 during necrosis. Cells that die in a programmed way 
(apoptosis) retain HMGB1 bound to chromatin remnants even after eventual cell lysis
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(Wang et al., 1999) and its motion is blocked: this behavior is characteristic of HMGB1 
and it has never been observed for other nuclear proteins. During apoptosis, HMGB1 is 
not post-translationally modified (Fig. 1.9a).
In contrast, when cells die in a nonprogrammed way (necrosis), they release 
HMGB1 by simple diffusion due to cytoplasmic membrane disruption. HMGB1 
deficient necrotic cells display a reduced inflammatory reponse if compared to wild type 
cells. This differential behavior between necrotic and apoptotic cells makes HMGB 1 the 
primary signal of tissue damage at least at injury site; extracellular HMGB1 promotes 
local and systemic responses in the organism, including inflammation and the activation 
of innate and adaptive immunity (Scaffidi et al., 2002)(Fig.l.9b).
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Fig. 1.9 H M GB1 release during cell death : a. active release; b. passive release (from  Y ang et al., 2005).
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1.5.3 Inflammatory response in vitro and in vivo
Extracellular HMGB1 activates a large number of different physiological responses in 
different cell types, and can be considered a cytokine (Muller et al., 2004). in vitro there 
are experimental evidences that macrophages, monocytes, endothelial cells, neutrophils, 
epithelial cells and dendritic cells can have a cytokine release activity related to HMGB 1 
during the response to inflammation stimuli. In particular, as inflammation is primarily 
mediated by macrophages, monocytes and endothelial cells, the most numerous 
publications in the field are about these cellular systems: due to the stimulation with 
HMGB1, a huge ensemble of cytokines like TNF, IL-1 (3, IL -la , IL-6, IL-8, M IP-la and 
MIP-ip are released by the first two types of cells, whereas endothelial cells release 
mainly ICAM-1, VCAM-1 and RAGE (see further), but also TNF and IL-8 like 
macrophages and monocytes. Interestingly, in cultures of umbilical endothelial human 
cells, the proinflammatory activity of the Box B of HMGB1 was demonstrated. 
Moreover, HMGB1 is able to interact destruptively with a endothelial monolayer, this 
suggesting a role of the protein in promoting inflammatory stimuli in the injury site of a 
tissue (Loetze et al., 2001)
In vivo HMGB1 inflammatory effects have been experimentally detected in 
brain, lung and joints. Also in inestinal tract (Sappington et al., 2002) and in heart 
(Germani et al., 2007) HMGB1 has a role in regulating inflammatory response, but in 
these last cases this role is still not clearly documented. In particular, in lung HMGB 1 
levels are very high in patients and mice with acute lung injury: in animal models the 
injection of HMGB1 lead to an increase of levels of TNF, ILlb and MIP-2 and to lung 
edema, whereas antibodies against HMGB1 are able to decrease both lung edema and 
neutrophil levels. Joints related HMGB1 studies are very important due to the intimate 
correlation with reumatoid arthritis: high HMGB1 levels have been found in the sinovial 
fluid of reumatoid arthritis patients, whereas in adjuvant arthritis animal models 
HMGB 1 is expressed in all cellular compartements compared to control animals where 
only nuclear HMGB1 is detected (Taniguchi et al., 2003).
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1.5.4 HMGB 1 receptor(s)
If the nuclear life of HMGB1 has been extensively characterized and the effect of 
HMGB1 on different types of cells has been fully investigated and it is well 
documented, many questions about the receptor of HMGB 1 are still open. Historically, 
the first identified HMGB 1 receptor was the receptor for advanced glycation endproduct 
(RAGE), a transmembrane protein belonging to the family of immunoglobulins and 
involved in many different receptor-ligand interactions (Bierhaus et al., 2006). RAGE is 
expressed in endothelial cells, in macrophages/monocytes and in vascular smooth cells, 
and its interactions with HMGB1 has been reported in tumour cells and in macrophages. 
In general, from a signaling point of view, RAGE is able to signal for the activation of 
two proteins, CDC42 and Rac, that regulate cell motility and neurite outgrowth 
(Huttunen et al., 2002). Moreover, RAGE is also able to activate a cascade of signals 
through the phosphorylation of many MAP kinases (p38, p42/44, ERK) and finally 
through the activation of the NF-kappaB pathway (Huttunen et al., 2002). Residues 
belonging to the C terminal part of HMGB1 Box B have been indicated as possible 
responsible for the interaction with RAGE. However, all these aforementioned 
evidences are not sufficient in order to explain all the biological effects of extracellular 
HMGB1. Moreover, there are serious doubts that RAGE is, at least, the only receptor of 
HMGB1 mainly because there are some experimental indications that show that 
HMGB 1-mediated effects are only partially reduced by blocking RAGE (i.e., by 
antibodies against the receptor) (Li et al., 2003). More recently some results evidenced 
that Toll like receptors (TLR) of type 2 and 4 are able to interact with HMGB1 leading 
to the activation of the NF-kappaB pathway. However, the implications of these 
interactions are still under investigation, like the hypothesis of a synergistic effect of 
RAGE and TLRs in binding extracellular HMGB1 (Yu et al., 2004).
1.5.5 Pathological relevance o f HMGB 1
HMGBl's importance in pathological aspects of inflammation has been already 
demonstrated in systemic inflammation diseases like sepsis, reumatoid arthritis and 
atherosclerosis.
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The systemic release of HMGB1 in murine models of sepsis (Wang et al., 1999) 
has been largely documented, and also in human patients HMGB1 levels are much 
higher than in healthy subjects. Interestingly the kinetics of HMGB1 release is delayed 
with respect to other cytokines, like the HMGB1 induced release of TNF in 
macrophages, hence indicating that HMGB1 does not act as an early acting cytokine, but 
its effect comes late after the injury.
In reumatoid arthritis, HMGB1 is found at high levels in junctions and in 
particular in sinovial fluids: injection of HMGB1 in joints of healty mice induce 
cytokines release by macrophages, including TNF, IL-lb and IL-6. These data suggest a 
role of HMGB1 in the cartilage damaging process typical of arthritis, inducing some 
groups in the recent years to investigate HMGB 1 as a marker of inflammation at least in 
this pathology (Taniguchi et al., 2003).
In the last five years also a role for HMGB1 has been also found in 
atherosclerosis (Porto et al., 2006), due to the release of HMGB 1 by smooth muscle cells 
(SMC) in human atheroscleotic plaques. SMCs proliferate, migrate, and actively secrete 
more HMGB 1 than other cells in response to HMGB 1 itself and, partially, in response to 
cholesterol loading.
1.5.6 Beneficial effects o f HMGB 1
Not only pathological detrimental effects of HMGB1 are known, but also beneficial 
ones. Extracellular HMGB1 induce both migration and proliferation of vessel-associated 
stem cells (mesoangioblasts) both in vitro and in vivo (Palumbo et al., 2005). It was 
demonstrated that alpha-sarcoglycan null dystrophic muscle cells contain elevated levels 
of HMGB 1, and mesoangioblasts were able to migrate into dystrophic muscles even if 
their RAGE receptors were disabled. This implies that the HMGB 1-RAGE interaction is 
sufficient, but not necessary, for mesoangioblast homing, hence HMGB1 can in 
principle be used in order to induce muscle tissue regeneration by simple injection.
Mouse models demonstrated that HMGB1 can cover an important role in left- 
ventricular function and myocyte regeneration after infarction (Limana et al., 2005): 
administration of HMGB1 in the left ventricle of an operated animal resulted in the
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formation of new myocytes within the infarcted portion of the wall. The regenerative 
process involved the proliferation and differentiation of endogenous cardiac c-kit+ 
progenitor cells. Echocardiographic and hemodynamic parameters at 1, 2, and 4 weeks 
demonstrated a significant recovery of cardiac performance in HMGB 1-treated mice.
1.5.7 Anti-HMGBl therapy
Up to date, a real anti-HMGBl drug does not exist, and a treatment of HMGB1 
involving disases or pathology is still missing. However, many steps in this direction 
have been made.
Antibodies against HMGB1 can reverse sepsis caused by peritonitis in mice 
(Kokkola et al., 2003; Yang et al., 2004); the effect of HMGB1 is dose dependent and it 
is effective only after TNF clearance during inflammation. Surprisingly, such a similar 
protective effect was observed also for the HMGB1 Box A, that thus acts as an 
anatagonist of HMGB1. These two “protein derived drugs” have also some beneficial 
effects on collagen induced arthritic pathologies in rodents, thus suggesting and anti- 
HMGBl strategy for the treatement of such a disease. Moreover, ethylpiruvate, a non 
toxic food additive, has been also tested as anti-inflammatory agent: it is able to inhibit 
the LPS induced HMGB1 release and the activation of the NF-kappaB and p38 MAPK 
pathways in macrophages (Ulloa et al., 2002).
1.5.8 Triterpenic drugs and interactions with HMGB1
Triterpenic drugs are the biochemical product of the tail to tail condensation of two 
molecules of pharnesyl pyrophosphate. They are traditionally named “saponins” because 
of their ability to decrease the surface tension of solutions (Goegelein et al., 1984) and to 
produce bubbles in them like soap: for this reason saponins are often used in chemical 
industries as surface pressure reducer. The most relevant biological property of saponins 
is the emolysis of eritrocytes (Baumann et al., 2000). In humans saponins are only 
poorly absorbed by intestinal walls and this makes them not toxic if orally administered 
(Samuelsson, 1999). Chemically, triterpenic saponins are characterized by the presence 
of a triterpenic scaffold (aglicone) connected through an ether bond to oligosaccaride
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Fig. 1.10 a. Structure of carbenoxolone [R(C)] and of glycyrrhizin [R(G)]; b. ursolic acid; c. oleanoic acid; 
d. lupeol.
chain composed of up to 12 sugar units (mono saccharides or uronic acids). If the 
triterpenic scaffold is substituted by steroidal scaffolds the whole class of compound is 
referred as “steroidal saponins” and it is the major natural source of hormones for 
pharmaceutical usage. One of the most important triterpenic natural drug is glycyrrhizin 
(Fig. 1.10a), whereas oleic acid, ursolic acid and lupeol are the three major sources of 
triterpenic scaffold for triterpenic saponins (Fig. 1.10b,c and d).
Glycyrrhizin (GL) is the name of the sodium or potassium salt of the
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glychirrizhic acid, whose triterpenic scaffold is called glychiritinic (or glychirretic) acid 
(Fig. 1.10a). The major sources of GL are the licorice root and the licorice extract, that 
contain up to 90% of the active principle and that can be obtained by 3 or 4 years old 
Glychirriza glabra, of the Fabaceae family, a 1-2 m tall plant that grows in the 
Mediterranean Sea area, in the South of Russia, in Iraq and in Iran. Licorice roots are 
grey-brown and are longitudinally striped; licorice extract is a viscous mass that is 
usually conserved in rods (Samuelsson, 1999). Other triterpens like b-amyrin, 
stigmasterol, onocerin and sitosterol are present in minor quantities in the licorice 
roots/extracts together with 30-40 different types of flavonoids, a small amount of 
cumarin and all the precursor of GL at small percentage (see Fig. 1.11) (Samuelsson,
1999).
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Fig. 1.11 G lycyrrhizin biosynthesis in plants (from  H ayashi et al., 2004).
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GL is widely used in food industry because of a taste 50 times sweeter than 
saccharides. Pharmacologically it has a relevant anti inflammatory and anti ulcer activity 
(see further), a still controversial expectorant activity and an anti diuretic activity, 
despite the fact that a prolonged usage can generate edemas. More in general side effects 
of GL are very similar to the ones of corticosteroids, i.e. hypertension, hypopotaxemy, 
lowered glucose tollerance (Samuelsson, 1999, Matsui et al. 2004).
Other sources of pharmacologically relevant triterpenic saponins are the roots of 
Quillaja saponaria, of Poligala senega and of Panax ginseng. The active principle of 
the first two plants are mainly used as expectorant; ginsenosids are derivative of 20(S) - 
protopanaxadiol and of 20(S) -  protopanaxtriol and are adaptogen drugs whose 
pharmacological activity towards platelets aggreagation, inflammation, CNS stimulation 
or depression has been documented in the last decade (Samuelsson, 1999).
For the past few decades, the GL preparation Stronger-Neo Minophagen C 
(SNMC) has extensively been used to treat chronic hepatitis in Japan (Arase et al. 
1997) , and the safety and efficacy of SNMC have established. SNMC is now under 
clinical trial in Europe in patients with chronic hepatitis C (van Rossum et al., 2001) . So 
far, GL has been demonstrated to have a variety of activities, such as the production of 
several cytokines, namely IFN-g, IL-2, IL-12, and IL-10, and the augmentation of NK 
cell/NKT cell activity (Matsui et al., 2004) . Also, GL administration induces anti­
inflammatory, cytoprotective effects in vivo and anti-viral effects in vitro (Shibata et al.,
2000). In early 2003, severe acute respiratory syndrome (SARS) raged in several 
countries. Surprisingly, it was promptly reported that GL was effective against SARS- 
associated coronavirus (Cinatl et al., 2003). A subsequent paper reported that an 
elevation of plasma inflammatory cytokines and chemokines was observed in SARS 
patients (Wong et al., 2004) and more recently it was experimentally demonstrated that 
GL and related compounds are able to down-regulate production of inflammatory 
chemokines IL-8 and eotaxin 1 in human lung fibroblasts (Sato et al., 2001).
Carbenoxolone (CBNX), a synthetic derivative of GL, is a licensed drug used for 
oesophageal ulceration and inflammation. Recently it has also been investigated for
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nootropic effects (Sandeep et al., 2004): moving from observations about negative 
effects on cognition and memory generated by long-term exposure to glucocorticoids, it 
was possible to monitor a CBNX induced decrease of the amount of active 
glucocortocoid in the brain due to the 11 Beta-hydroxy steroid dehydrogenase type 1 
inhibition. CBNX side effects are the same of GL.
In 2001 (Sakamoto et al., 2001) it was demonstrated in vitro that there is a 
physiological correlation between GL and high mobility group proteins 1 and 2 (HMG1 
and HMGB2) and the inhibitory effect of GL on their phosphorylation by three protein 
kinases (CK-I, CK-II and PKC). It was found that HMG 1/2 have a high affinity with a 
GL-affinity column and that GL induces a small conformational change in HMG 1/2 
(revealed by a change in the CD spectrum between the free and the bound state of the 
protein). Phosphorylation of HMG 1/2 by two protein kinases (CK-I and PKC) was 
completely inhibited by a glycyrrhetinic acid derivative (oGA) at one-tenth the 
concentration of GL. Also, the DNA-binding abilities of HMG1/2 were reduced by GL 
in a dose-dependent manner. These results suggest that the binding of GL to HMG 1/2 
results in the inhibition of their physiological activities (DNA-binding ability and 
phosphorylation by PKC or CK-I) in vitro.
More recently, G.Sitia and collaborators (Sitia et al., 2007) demonstrated in vivo 
the effect of GL on HMGB1 in Hepathitis B Virus (HBV) mice models. The authors 
found that HMGB1 is not involved in the migratory and antiviral activity of virus- 
specific , but it is necessary for the intrahepatic recruitment of antigen non-specific cells 
that amplify the cytotoxic T lymphocytes (CTL) dependent liver damage, suggesting 
that a similar role of HMGB 1 could be played in the pathogenesis of viral hepatitis in 
man. Since the treatment of mice with Box A-A or GL is associated with maintenance of 
CTL-dependent antiviral effects but diminished tissue damage, the design of new and 
more potent inhibitors of HMGB1 may be useful for the treatment of chronic HBV 
infection. Along these lines these results shed new light into the mechanism whereby GL 
may carry out its beneficial effect.
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1.6 Preliminary results
1.6.1 Glycyrrhizin inhibits the chemoattractant Activity o f HMGB 1 
HMGB1 has chemoattractant activity on endothelial, smooth muscle, and vessel- 
associated stem cells (Palumbo et al., 2004). In addition, M arco E. Bianchi and 
coworkers (personal communication) demonstrated that it is also a powerful 
chemoattractant for the widely available mouse 3T3 fibroblasts (Fig. 1.12). GL 
interfered with HMGB 1-elicited cell migration of 3T3 fibroblasts in a dose-dependent 
m anner (p < 0.001 in ANOVA two-way test). The number of 3T3 cells migrating in
■no chemo­attractant
-r [ ]  0.1 nM fMLP
^  Q  1 nM HMGB1
200 glycyrrhizin (pM)
Fig. 1.12 3T3 fibroblasts w ere subjected to chem otaxis assays in B oyden cham bers where 0.1 nM  fM LP, 1 
nM  H M G B 1, or no chem oattractant was added in the low er cham ber, together w ith the indicated 
concentrations o f  glycyrrhizin. The data represent the average ± SD of three replicates; the experim ents 
w ere replicated at least three times. The inhibitory effects o f glycyrrhizin on H M GB 1-induced cell 
m igration w ere highly significant (p < 0.001 in A N O V A  analysis), w hereas they w ere no t statistically 
significant on fM LP-induced cell m igration.
response to 1 nM HMGB 1 was reduced by about half at a concentration of 50 mM GL 
(IC50 = 4 9 +  1 mM in a sigmoidal log dose response curve, r2 = 0.93). GL did not affect 
cell migration elicited by fMLP, a well-known chemoattractant, even at a concentration 
of 200 mM. This shows that GL does not affect the general mobility of fibroblasts, and 
suggests that its effect is specific on HMGB 1 -elicited chemotaxis. Moreover, GL had no
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statistically significant effect on the mobility of fibroblasts in the absence of 
chemoattractant.
HMGB1 promotes the in vitro proliferation of vessel associated stem cells 
(mesoangioblasts) in the absence of fetal calf serum (Palumbo et al., 2004). When added 
to mesoangioblasts in culture, increasing concentrations of GL inhibited the mitogenic
.5
4
,2 HMGB1
HMGB1 +25 (jM glycy
HMGB1 + 50 pM glycy1
HMGB1 + 200 pM glycy
no serum, no HMGB1
0
3 days20 1
F ig .1.13 D16 m esoangioblasts w ere grow n in RPM I m edium  containing no additions, 1 nM  HMGB1 w ith 
the indicated concentration  o f g lycyrrhizin, or 20%  fetal calf serum  (FCS). Each point represents the m ean 
o f three replicates. E rror bars are om itted to avoid clutter; the standard deviation w as betw een 2% and 
15% o f the average. T he experim ent w as repeated three times. The inhibitory activity o f  glycyrrhizin 
HM GB 1-induced stem -cell proliferation  is highly significant (p < 0.001 in A N O V A  analysis).
activity of HMGB 1 in a dose-response manner; in the presence of 200 mM GL no 
mitogenic activity of HMGB1 was noted, and the cell counts were indistinguishable 
from those of cultures where no serum and no HMGB1 were present (Fig. 1.13).
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1.6.2 Glycyrrhizin does not interfere with the nuclear function o f  HM GB 1 
In order to test if GL might interfere with the DNA-binding function of HMGB1, 
fluorescence recovery after photobleaching (FRAP) experiments in order to monitor 
whether GL would increase the mobility o f intranuclear FIMGB1, and reduce its 
residence time on chromatin (Fig. 1.14). In the presence of 100 mM of GL, the mobility
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Fig. 1.14 a. FR A P analysis of H M G B 1-G FP in living 3T3 fibroblasts incubated in the presence or absence 
o f 100 m M  glycyrrhizin for 4 hr or overnight. C om pare for reference the m obility o f an HM GB1 m utant 
unable to bind D NA  (m utH M G B I). D ots indicate m ean values, and error bars indicate standard error, 
from  eight cells. A lso shown is an enlargem ent o f the recovery kinetics in the first 2 s. The effect o f  
glycyrrhizin is statistically significant (p < 0.01 in paired tw o-w ay t test), b. FR A P analysis o f H M G B 1- 
G FP in 3T3 fibroblasts undergoing apoptosis fo r 16 hr after addition o f 2 ng/ml TN F-a and 35 m M  
cyclohexim ide in the presence or absence o f  100 mM  glycyrrhizin. Only two cells per class are show n out 
o f seven analyzed, to avoid clutter. The difference betw een treated and untreated apoptotic cells is not 
statistically  significant (M ann-W hitney test). For reference, the recovery kinetics o f HMGB1 in living 
cells is indicated.
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of HMGB 1-green fluorescent protein (GFP) increased a little after 4 hr (p < 0.01, 
ANOVA), and slightly more after overnight incubation, indicating that GL can indeed 
interfere with the binding of HMGB1 to DNA in living cells. However, the GL-induced 
increase in the mobility of intranuclear HMGB 1-GFP was quantitatively modest, and far 
from the mobility of an HMGB 1-GFP mutant that does not bind DNA (Agresti et al.,
2005). This suggests that the effect of GL on the intranuclear functions of HMGB1 is 
modest. We also tested whether GL might interfere with the tight binding of HMGB 1 to 
apoptotic chromatin (Scaffidi et al., 2002). Fibroblasts were induced to undergo 
apoptosis after exposure to TNF-a, in the presence or absence of 100 mM GL, and the 
mobility of HMGB 1-GFP was measured by FRAP. HMGB 1-GFP was immobilized both 
in cells treated and not treated with GL (Fig. 1.14).
1.7 Synopsis of the presented work
Starting from the observations about the possible interactions between triterpenic drugs 
and HMGB1 and moving from the results that indicate that a small molecule based 
therapy against HMGB1 is possible, we have investigated the nature of the binding of 
GL (and its derivative CBNX) to HMGB 1 and provided an atomic level description of 
the protein-ligand complex. We adopted a hybrid experimental and computational 
approach that combined nuclear magnetic resonance spectroscopy, fluorescence 
spectroscopy and molecular dynamics and quantum mechanical calculations. The 
results of the thesis have been divided into two parts: a. the experimental results b. the 
structure calculations.
This work is intended as the first step towards the comprehension of the 
molecular mechanism that govern the effect of triterpenic drugs on HMGB1 induced 
inflammatory response and a necessary preliminary step for GL based drug design.
1.7.1 Synopsis o f the experimental results
In the first part of the work (Chapter 3) the direct binding between protein and 
ligands is demonstrated, a Kd is reported (determined both by NMR and fluorescence 
spectrosopies) and the region of the protein that is involved in direct contact with the
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ligand is reported as determined by the chemical shift difference (CSD) mapping 
method. Local mobility and overall diffusion for each HMGB1 Box in the free and 
bound forms has been studied by means of 15N spin relaxation measurements, 
demonstrating the effect of the binding on the local stability and residual mobility of the 
protein on different timescales.
1.7.2 Synopsis o f the structure calculations
In the second part of this thesis (Chapter 4) the problem of determining an atomic 
level description of the protein is faced: due to a quite high Kd it was not possible to treat 
the structure determination of the complex in a standard way {i.e., distance restraints 
based structure determination), hence two different computational approach have been 
used for carbenoxolone (QRFF method) and for GL (data driven docking by 
HADDOCK) leading to a final model of the complexes that take into account all the 
experimental data collected on the system.
1.7.2.1 QRFF methodology
In the Quantum Refined Force Field methodology (Curioni et al., 2004) a set of 
molecular dynamics simulations is performed on the Box A - CBNX system starting 
from a structure obtained by standard {i.e., using standard force fields) docking 
procedures based upon the knowledge of the ligand binding site and letting the system 
free to evolve towards minima. The system topology {i.e., the ensemble of descriptors of 
molecular charges, bonds, plain angles and dihedral angles) has been built using a set of 
“protein tailored” parameters {i.e., the GROMOS96 force field) for describing the inter- 
and intramolecular forces between the protein residues and between the protein, the 
ligand, the solvent and ions, adopting a quantum mechanical method to modify the 
parameters that describe the interactions of the ligand with the environment. This 
procedure is suggested by the different chemical nature of the protein and of the ligand 
that makes the representation of the latter less precise than the one of the former: due to 
the long-standing interest in protein simulation by means of molecular mechanics, 
available force fields for peptides have been frequently tested against experimental data
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for a long time, hence they are more reliable in representing peptides dynamics than 
small molecules dynamics. This is also due to the relatively small chemical variability of 
proteins with respect to the huge variability of organic compounds, that in this sense are 
less prone to be parametrized.
The quantum mechanical method adopted is the plane waves scheme of DFT as 
implemented in the software CPMD (CPMD). The main feature of the QRFF procedure 
is the correction of the protein-based charges of the ligand: moreover, in the present 
work also a correction of dihedral angles is presented according to the calculation of 
vibrational spectrum of the CBNX molecule.
1.7.2.2 HADDOCK methodology
The molecule of main interest for the present study is GL. However, due to the 
difficult representation of sugars in the aforementioned molecular mechanics/dynamics 
scheme, the QRFF methodology cannot be easily implemented for the study of GL 
complexes with HMGB1 Box A and Box B. This led to the choice of a different method 
for the determination of the atomic level structure of these complexes: a docking scheme 
was adopted that could incorporate a set of experimental data that could “drive” the 
placing of the ligand on the surface of the macromolecule. This scheme is usually 
referred as data driven docking, and it is used as implemented in the HADDOCK 
package: the experimental data used as input are chemical shift displacement (CSD), 15N 
spin relaxation, [H-15N residual dipolar couplings (RDCs) and protein ligand NOEs. The 
whole set of experimental data are used in the early stages of docking (i.e., rigid body 
docking) in order to find the correct relative “poses” of the two molecules that best 
satisfy the experimental information. The whole procedure is performed by a molecular 
mechanics engine based on the package CNS (Dominguez et al., 2003): after the initial 
stage that generates a large set of poses, the resulting structures are refined according to 
local sidechain flexibility and to the solvation of residues.
The HADDOCK based approach, with respect to the QRFF methodology, makes 
large use of experimental data to restraint the range of possibilities of protein-ligand 
poses: in this sense it is “logically” opposite to the previously presented approach, that
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starts from an approximately determined position of the ligand and determines the best 
configuration of the complex only using first physical principles. The aim of the work is 
to determine the structure of the complex adopting different strategies according to the 
chemical difference and complexity of the molecule. Moreover, a comparison can be 
made between the two methods with respect to structural proteomics or drug discovery 
future projects.
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2. Materials and Methods
2.1 Protein Expression and Purification
Recombinant HMGB1 constructs comprising Box A (residues 1-89), Box B (residues 
90-175), and the full-length protein were cloned in a modified pET-24d vector 
(Novagen, Madison, WI) expressing a protein with an N-terminal 6-His tag, removable 
by cleavage with TEV protease. After expression and cleavage with TEV protease, the 
proteins have a residual N-terminal three-residue tag (GAM). Escherichia coli BL21 
(DE3) cells were grown at 37°C until the optical density at 600 nm reached 0.8 
absorbance units. Gene expression was induced by the addition of isopropyl (3-D-l- 
thiogalactopyranoside (IPTG) to a final concentration of 1 mM. After 18 hr incubation at 
25°C with shaking, cells were harvested by centrifugation. The cells were resuspended 
in lysis buffer (20 mM Tris-HCl (pH 8.0), 0.15 M NaCl, 10 mM imidazole, 2 mM (3- 
mercaptoethanol, 0.2% NP40) and lysed by sonication. Cell debris was removed by 
centrifugation at 13,000 rpm for 30 min at 4°C in a microcentrifuge. The soluble 6-His- 
tagged HMGB1 protein was purified from the supernatant by affinity chromatography 
using Ni2+-NTA agarose resin (Qiagen, Hilden, Germany). After several (at least 4) 
washing steps, protein was eluted in 20 mM Tris (pH 8.0), 0.15 M NaCl, 0.3 M 
imidazole, 2 mM (3-mercaptoethanol, and the 6-His tag was removed by overnight 
incubation at 25C with TEV protease. During incubation, the sample was dialyzed 
against 20 mM Tris (pH 8.0), 0.15 M NaCl, 2 mM bmercaptoethanol: the uncleaved 6- 
His-tagged protein and the TEV protease were then removed by repassing the sample 
over Ni2+-NTA resin. The protein sample was further purified on a HitrapQ ion- 
exchange column followed by gel filtration on a Superdex-75 column (Amersham 
Biosciences, Milan, Italy) equilibrated in 40 mM Tris (pH 8.0), 0.2MNaCl, 3mM 
dithiothreitol (DTT). All the purified HMGB1 polypeptides were exchanged into 
appropriate buffers for NMR (20 mM sodium phosphate (pH 7.3), 0.15 M NaCl, 5 mM 
DTT, 0.02% NaN3, 5% v/v D20). Uniformly 15N- and 15N/13C-labeled proteins were 
prepared using M9 minimal bacterial growth media appropriately supplemented with
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15N-labeled ammonium chloride and I3C-labeled glucose. Protein concentration was 
determined measuring the absorbance at 280 nm considering molar extinction 
coefficients of 9,186, 10,810, and 19,666 M '1 cm'1 for Box A, Box B, and HMGB1, 
respectively.
2.2 NMR Experiments
2.2.1 Ligands assignment
Carbenoxolone and Glycyrrhizin spectra were recorded at 298K on a Bruker Avance 
500MHz spectrometer equipped with inverse triple-resonance probe and pulsed-field 
gradients, and processed with NMRPipe (Delaglio et al., 1995). Resonances were 
obtained and assigned from proton spectra with excitation sculpting scheme for water 
suppression (Hwang et al., 1995), 13C edited HSQC (Wilker et al. 1993), HSQC-DEPT 
(Palmer III et al., 1991), HMBC (Bax et al. 1986), COSY (Aue et al., 1976), TOCSY 
(Bax et al. 1985) and NOESY (Neuhaus et al., 2000). All the experiments have been 
performed on natural abundance samples at a concentration of 5 mM in 20 mM 
phosphate buffer (pH 7.3). The ligand numbering scheme is reported for Carbenoxolone 
in Fig.2.1; the same has been adopted for Glycyrrhizin triterpenic scaffold.
2.2.2 Proteins assignment and titrations.
NMR spectra of the free and bound protein were recorded at 298K on a Bruker Avance 
600 MHz spectrometer (Karlsruhe, Germany) equipped with inverse triple-resonance 
cryoprobe and pulsed-field gradients. Spectra were processed with NMRPipe (Delaglio 
et al., 1995) and analyzed using XEASY (Bartels et al., 1995), PIPP (Garrett et al.,
1991) and/or NMRView (Johnson et al., 1994). The 1H,13C,15N assignment of the 
backbone resonances of Box A, Box B, and full-length HMGB1 were obtained from 
HNCA (Witterkind et al., 1993), HNCACB and CT-HNCO (S. Grzesiek et al., 1992) 
with water-flip-back modifications (S. Grzesiek et al., 1993) and CBCA(CO)NH (S. 
Grzesiek et al., 1992) with WATERGATE scheme for water suppression (Piotto et al.,
1992) using uniformly 15N,13C-labeled samples.
Typical protein concentration for NMR titration experiments was 0.3 mM in 20
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Fig.2.1 The chem ical structure o f  C arbenoxolone. The enum eration adopted for C arbenoxolone is the 
sam e adopted for the triterpenic scaffold o f  G lycyrrhizin.
mM phosphate buffer (pH 7.3), 150 mM NaCl, 5 mM DTT. In order to minimize 
dilution and NM R signal loss, titrations were carried out by adding to the protein 
samples small aliquots of a concentrated (10 mM) ligand stock solution (glycyrrhizic 
acid monoammonium salt trihydrate, 98% purity (Acros Organics, Geels, Belgium), 
carbenoxolone disodium salt, 98% purity (Sigma, St. Louis, MO) in 20 mM phosphate 
buffer, 150 mM NaCl, at pH 7.3. For each titration point (typically 0.25, 0.5, 0.75, 1, 
1.5, 2, 3, 4 equivalents of ligand), a two-dimensional water-flip-back 1:,N-edited HSQC 
spectrum was acquired with 512 (100) complex points, 55 ms (60 ms) acquisition times, 
apodized by 60 shifted squared (sine) window functions, and zero filled to 1024 (512) 
points for 'H (and 15N), respectively. Assignment of the corresponding amide groups in 
the complexes was made by following individual crosspeaks through the titration series. 
For each residue, the weighted average of the 'H and l5N chemical shift difference was 
calculated (Fielding, 2003) as
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A 5 ‘ HN+ ( 2 .1 )
Binding constants of glycyrrhizin to single Boxes (Box A and Box B) were 
estimated by monitoring the variation of CSD of individual peaks (eight peaks for each 
Box). Assuming a simple binary reaction between protein and ligand, dissociation 
constants were obtained from least squares fitting of CSD as a function of total ligand 
concentration according to the quadratic equation (Equation 1):
with a -  (Kj8b)(Pt), b = 1 + Ka((Lt) + (PJ) and c = dbKa(Lt), where S, is the absolute 
change in chemical shift for each titration point, (L„) is the total ligand concentration at 
each titration point, (Pt) is the total protein concentration, Ka = 1/Kd is the binding 
constant, and 5t is the chemical shift of the resonance in the complex (Fielding et al., 
2003). Kd and & were used as fitting parameters using the Xmgrace program 
(http://plasma-gate.weizmann.ac.il/Grace/).
The proton chemical shifts of the bound glycyrrhizin and carbenoxolone were 
assigned by 15N/13C filter, 15N/13C-filtered TOCSY (60 ms) and 15N/13C filter, 15N/ 
13C-filtered NOESY (120 ms) experiments. Intermolecular NOEs between glycyrrhizin/ 
carbenoxolone and Box A were obtained from 2D NOESY experiments with 15N/13C 
filter in F2 (mixing time 70-120 ms) (Breeze, 2000); protein and ligand concentration 
were 0.6 mM and 0.9 mM, respectively.
2.2.3 Saturation Transfer Difference (STD) measurements
The STD measurements were performed on a Bruker DMX-500 MHz spectrometer 
employing a pulse scheme with WATERGATE water suppression and T>, filter (Mayer
b - ^ b 2- 4 a c  
0;=  1-------- a
(2 .2)
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and Meyer, 2001). The irradiation power (expressed in yB]/2Ti units ) was 20 Hz, which 
was applied on-resonance at 7 ppm or off-resonance at -12 ppm. The relaxation delay 
was set to 5 s to allow the ligands to relax between on and off-resonance irradiation 
cycles. A set of 7 spectra was collected for each complex, and the STD spectrum 
collected at each tsat was the sum of 64 scans. The 10 spectra corresponded to the 
following saturation time: 0.2, 0.3, 0.6, 1.2, 1.8, 2.4 and 3.6 s.
2.2.4 Relaxation Measurements
All NMR experiments for the determination of 15N spin relaxation were performed at 
298K on a Bruker Avance 600 MHz (Karlsruhe) spectrometer with a cryogenic TCI 
probe. 15N spin Ti, T2, and {1H}-15N (heteronuclear) NOE (hetNOE) NMR experiments 
were performed for both the unliganded and liganded forms of both Box A and Box B 
(0.5 mM of 15N labelled samples, pH 7.2, 20mM phosphate buffer) using sensitivity- 
enhanced pulse field gradient sequences (Farrow et al. 1994): heating effects were 
minimized in all spin relaxation experiments by collecting the data as interleaved 
pseudo-3D spectra. Ti data were acquired with the following 14 relaxation delays: 
20(duplicated for error analysis), 50, 100, 150, 200, 250, 370, 500, 650, 800, 1000, 
1300, 1600, 2000 msec. T2 data were obtained with the following 12 relaxation delays:
13.1 (duplicated for error analysis), 26.3, 39.5, 52.6, 65.7, 78.9, 105.1, 118.3, 131.1, 
157.7, 184 msec. Both T L and T2 experiments use a 2.5 seconds recycle delay. The 
{1H}-15N NOEs were measured by recording HSQC (Farrow et al., 1994) spectra with 
and without proton saturation: this spectrum has been recorded in an interleaved fashion 
using a 3 seconds recycle delay.
Ti, T2 and hetNOE values have been obtained using the fitting routine 
implemented in the analysis program NMRView (Johnson et al.,1994) integrated with 
homemade scripts in Bash native language and in Tcl/Tk language for automation and 
efficient and fast data handling. The values have been extracted from the peak volume 
(V) decay curves using the two parameter exponential curve
using a least squares fitting procedure with 100 iterations.
Correlation times xc that have been obtained from Ti and T2 using the empirical 
relationship:
T
6R2
R
- 1 (2.4)
Residues undergoing large amplitude fast motions have been detected by means 
of heteronuclear NOEs data (Tjandra et al., 1996). Residues (10-15% of the total 
amount) with too low values of NOE (< 0.65) have been excluded during the data 
analysis because of the weight they could have in the overall diffusional dynamics 
interpreted using a rigid body approach. Data have also been checked for residues that 
undergo slow motions due to chemical exchange related to anisotropic motion/difusion: 
they can be easily distinguished among the other low T2 values through the error 
analysis of Ti using the criteria that follow (Barbato et al., 1992):
The goodness of fit of and T2 onto this diffusional tensor and of associated 
errors has been analyzed using a 500 steps Montecarlo simulated annealing procedure as 
implemented in the software TENSOR2 starting from the predicted best fit of diffusional 
tensor. An F test allowed the discrimination between a fully symmetric, axially 
symmetric or fully asymmetric model for the description of the overal diffusional 
motion of the protein (Dosset et al., 2000).
Lipari-Szabo “model-free” analysis of relaxation data has been performed with 
the help of the program TENSOR2 (Dosset et al., 2000).
(T2) ~T2!> a (2.5)
(2 .6)
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2.2.515N-lH  Residual Dipolar Couplings (RDCs)
The 15N-’H RDC measurement were performed adopting the method of acrylamide 
cylindrical gels axial compression described by Grzesiek and coworkers (Sass et al.,
2001): this alignment medium was chosen because of the highly negative charge of 
HMGB1 that disallowed the usage of phages (a negatively charged alignment media) 
due to strong electrostatic interactions that lead to pronounced signal broadening and/or 
peak disappearance (only a total amount of ~ 10 signals resulted detectable considering 
the the two Boxes). A cylindrical plastic tube of suitable 3.5 mm was closed on one end 
by parafilm. An acrylamide solution was prepared at the final percentage of 6% from a 
stock of 29.2% w/v acrylamide and 0.78% w/v N,N0 -methylenebisacrylamide. 250uL 
of the 6% acrylamide solution was filled into the tube, just after the polymerization 
started by the addition of 0.1%w/v ammoniumpersulfate and 0.5% w/v 
tetramethylethylenediamine (TEMED). After polymerization was complete, the gel was 
pushed out from the tube by the application of gentle air pressure by means of a syringe: 
at this stage the gel presented a legth of 22 mm. After washing 5 times the gel in 40mL 
of MilliQ water for 10 minutes under gentle shaking it was dried over night on a smooth 
plastic support at 37°C in a drying oven. The dried gel was then placed into an NMR 
shigemi sample tube and 310|iL of buffer solution containing up to 0.3 mM of protein 
or complexes (Box A or Box B alone or complexed with GL) was then added. After 3-4 
h of swelling, the gel had filled out the sample tube and high resolution NMR 
measurements could be performed after axial pressure exerted by the plunger until the 
gel reached a length of 15 mm. The whole procedure is summerized in gel and tube 
pictures in Fig.2.2. The RDCs measurements were performed on a Bruker DMX-500 
MHz spectrometer: a sensitivity-enhanced HSQC experiment that separates the upfield 
and downfield components in the indirect dimension into different subspectra with a 
sequence similar to the generalized TROSY scheme and decoupling of the N-nucleus 
during detection was performed for each sample (Cordier et al., 1999). The same kind of
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F ig .2.2 A crylam ide gel cylinder preparation for the RD Cs m easurem ents in a shigem i tube: a. the 
polym erized acrylam ide gel cylinder; b. the gel cylinder dried and inserted in the shigemi tube; c. the gel 
during sw elling w ith the protein solution; d. the gel com pletely rehydrated and pressed by the shigem i 
plunger. Real dim ensions are reported on the p icture.experim ent w as repeated for sim ple solutions o f 
proteins and com plexes w ithout acrylam ide gels in order to get a set o f  reference spectra.
All the data have been first visually inspected with the help o f M ODULE (Dosset 
et al., 2001) and analyzed with the DC program implemented in nmrPipe suite (Delaglio 
et al, 1995). The Q factors (Cornilescu et al, 1998) with respect to all the the available 
structure were computed according to the following formula:
n _ ^  I D C ^ - D C *
Q- \ i N D](A+3R>V5 ^
where DCcaic and DCnhs are respectively the dipolar couplings calculated (i.e., from a
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structure provided) and observed for each residues, N  is the number of DC values 
considered ,Da = D J2  is the axial component of the order tensor D expressed in terms 
of its eigenvalues and R = 2(D^ - is the rhomboedricity of the tensor.
2.3 Docking, Molecular Mechanics and Quantum Mechanics Calculations
2.3.1 Protein only simulations
All the molecular dynamics simulations on HMGB1 Boxes A and B have been 
performed using GROMACS 3.2 and GROMACS 3.3 (Berendsen et al., 1995) the force 
field adopted was the implemented GROMOS 43al (van Gunsteren et al., 1996). The 
calculations were performed on a 56 CPUs IBM eServer BladeCenter equipped with 
Myrinet communication system.
Box A and Box B structures used for performing MD simulations were obtained 
as average structures of the bundles of structures deposited on the Protein Data Bank 
with accession ID laab and lhmf respectively (Weir ert al., 1993; Hardman et al., 1995): 
the structures included in the bundles have a backbone RMSD (computed with respect to 
the average structures) of 0.8 + 0.2 A and of 0.9 + 0.2 A for Box A and Box B 
respectively. The protonation state considered for the simulations was for both the 
HMGB1 Boxes the one corresponding to pH 7, i.e., with protonated histidines and with 
Asp, Glu, Lys and Arg charges fixed at their native values, consistent with the neutral 
environment. Starting systems for the MD simulations were built with the help of the 
Visual Molecular Dynamics visualizer (VMD) (Humphrey et al., 1996) in order to a. 
place the protein in the geometric center of the simulation box; b. ensure enough 
distance between the surface of the protein and the Box edges, i.e. in order to ensure no 
interactions of the protein with its periodic images in the combined PBC/PME treatment 
(see further). The systems built in this way consisted of the protein, water molecules (~ 
17100 in both cases) and counterions (7 chloride ions for Box A and 6 for Box B) added 
in order to balance the system net charge. Proteins and water were coupled separately to 
a temperature bath at 300 K, using a Berendsen thermostat (Berendsen et al., 1984) with
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a coupling constant t 0.1 ps. In all simulations the pressure was kept at 1.0 bar using 
isotropic pressure coupling (Berendsen et al., 1984) with p 1 ps, hence obtaining an 
isocoric-isobaric simulation ensemble. Bond lengths were constrained using the LINCS 
algorithm (Hess et al., 1997) and Lennard-Jones interactions were calculated with a 
0.9/1.4 nm twin-range cutoff. The short-range electrostatic interactions were calculated 
to 0.9 nm, and the Particle Mesh Ewald (PME) algorithm was used for the long-range 
interactions. All trajectories were calculated in periodic rectangular Boxes of explicit 
simple point charge (SPC) water molecules (Berendsen et al., 1981). Periodic boundary 
conditions were applied in all the three cartesian dimensions. Solvent was equilibrated 
by 500 ps of solute position restrained MD with a force constant of 1000 kJ mol'1 nm'1, 
followed by 10 ns of unrestrained MD with a 2 fs time step.
In order to obtain an improved sampling of the phase space of the proteins 
(especially in more flexible regions) and to overcome any local minimum present on 
potential energy surface of the protein in solution, a Replica Exchange Molecular 
Dynamics scheme (Mitsutake et al. 2001) has also been adopted for both the systems in 
NPT ensemble. For Box A and Box B REMD simulations with 16 replicas (with a 
simulation time of 5ns for each replica) have been performed: temperature difference 
between neighboring replicas was set between 2 and 4 K, ensuring an exchange rate 
between 10 and 20% for each pair of neighboring replicas. The simulation parameters 
adopted, for sake of comparison, were the same indicated above for “standard” 
molecular dynamics simulations of Box A and B.
2.3.2 Box A-Carbenoxolone complex simulations
Molecular dynamics simulations have been performed in order to describe the dynamical 
behaviour of the Box A -  Carbenoxolone complex in solution and find a relationship 
with the experimental data. Due to the incorrect representation of small ligands using 
protein-tailored force fields in the most common MD codes, especially for what 
concerns electrostatics, a more detailed treatment of ligand charges is required.
We created the ligand (i.e., carbenoxolone) GROMOS topology using the 
PRODRG (Schuettenkolpf et al., 2004) web based software considering deprotonated
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oxygen atoms (i.e., charge state of the molecule was +2). These were later modified 
according to the QRFF method (Curioni et al., 2004), which produces quantum-refined 
charges consistent with the original parameterization, thus maintaining the balance 
between electrostatic and van der Waals forces. The central step of this procedure 
consisted of ab initio calculations of the ligand and of its electron density based on 
density-functional theory (DFT) as implemented in the Car-Parinello Molecular 
Dynamics package (CPMD). This specific DFT implementation used the Becke-Lee- 
Yang-Parr (BLYP; Becke, 1988) exchange-correlation functional, norm-conserving 
pseudopotentials (Troullier et al., 1993) and a plane-wave basis set with a 70 Ry cutoff.
First the structure of CBNX (Fig.2.1) was extracted from its complex with 3 
alpha, 20 beta-hydroxysteroid dehydrogenase (Ghosh et al., 1994) and optimized within 
DFT-BLYP, starting from one reported for this ligand in another complex . The changes 
of bond-lengths with respect to these experimental data were of the order of 0.01 A with 
the exception of the C -0  double bond which was 0.1 A larger. The refined values of the 
effective charges (given in Fig. 2.3a) were then derived from a restrained fitting (Curioni 
et al., 2004) to the DFT electrostatic potential as in previous applications (Ferrara et al.,
2006). In particular, for the atoms not included in the GROMOS parameterization (i.e., 
hydrogen atoms), the restraint value of the effective charges was set to zero.
To ensure the transferability of the QRFF, the final values were obtained as 
averages over 20 distinct conformations of the CBNX extracted from a 1 ns trajectory 
(every 50 ps) of GROMOS-based MD simulations of the ligand-protein complex in 
water: the simulation was performed using the software package GROMACS 3.3 and the 
parameters used for this simulation were the same indicated in the previous subsection 
(cl). CBNX configurations did not change substantially over the whole trajectory, thus 
revealing a certain rigidity of the ligand in the complex and resulting in a maximum 
deviation of 5% on the effective charges. However, as expected, they were very different 
from that of the molecule at equilibrium in vacuum. The average values, which were 
used in the calculations, are reported in Table 2.1 and compared to the unrefined ones.
The deviation from the unrefined values is shown in Fig. 2.3b for all atoms.
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GROMOS Atom 
Type
Atom
Name
charges
PRODRG charges QRFF
CH2 Cl 0.000 -0.078
CH2 C2 0.049 -0.005
CS1 C3 0.242 0.308
CHI C4 0.000 0.231
CHI C5 0.000 -0.125
CH2 C6 0.000 0.006
CH2 C l 0.000 -0.109
CHI C8 0.000 0.188
CHI C9 0.146 0.025
CHI CIO 0.198 0.318
CB C ll 0.157 0.227
R61 C12 -0.036 0.027
CB C13 -0.052 -0.210
CHI C14 0.000 0.238
CH2 C15 0.000 -0.047
CH2 C16 0.000 -0.107
CHI C17 0.000 0.274
CHI C18 0.088 0.200
CH3 C19 0.001 -0.090
CH2 C20 0.000 -0.095
CHI C21 0.139 0.310
CH2 C22 0.039 -0.140
CH2 C23 0.000 -0.069
CH3 C24 0.000 -0.111
CH3 C25 0.000 -0.089
CH3 C26 0.000 -0.104
CH3 C27 0.000 -0.097
CH3 C28 0.000 -0.144
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c C29 0.434 0.612
CH2 C30 0.041 0.028
CH2 C31 0.041 -0.102
C C32 0.364 0.879
C C33 0.346 0.833
CH3 C34 0.000 -0.190
OS 03 -0.160 -0.390
O O il -0.502 -0.458
O 029 -0.565 -0.624
OM 032 -0.723 -0.843
OM 033 -0.723 -0.846
OM 034 -0.762 -0.816
OM 035 -0.762 -0.816
Table 2.1 Values of the effective atomic charges in the PRODRG and in the QRFF parametrization.
Clearly the refinement is active all over the molecule, but the major changes pertain to 
the carbon atoms of the carbonyl endgroups. The major change relative to the 
PRODRG-derived values was found for the C(ll)-C(12) bond consistent with its partial 
double-bond character. Moreover the value of an improper dihedral term, involving 
C(11), C(12), C(13) and 0(11), that was missing in the PRODRG parameterization, was 
introduced (as an additional force constat) as obtained from our DFT calculations 
(2448.6 kJ nm2 m ol1).
The initial step for the identification of the binding site was made on the basis of 
the information derived from chemical shift perturbation data and of a standard docking 
procedure using AUTODOCK (Morris et al., 1998). The system for the molecular 
dynamics run was setup as previously indicated and the same parameters have been
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used: the simulation box was first minimized using a steepest descent algorithm and the 
solvent was equilibrated separately, afterwards it was allowed to evolve in an NVT 
ensemble until it stabilized itself within the last 2 ns of the run. To verify of our results 
we employed the replica-exchange MD method (REMD) (Mitsutake et al. 2001) and ran 
simulations keeping the number of particles fixed in the isocore-isothermal ensemble 
(66 ns). The replicas covered the range between 300 and 370 K, with an interval of 2-4 
K. A further attempt to verify our predictions with an analogous protocol was done 
adopting an isobaric-isothermal ensemble (11 ns).
For the sake of comparison, a simulation has been performed with the same 
protocol as above using the unrefined FF. Again, a subsequent REMD simulation (in 
the interval 300-370 K for 60 ns total time) was performed in order to verify the validity 
of our results.
2.3.3 Experimentally driven docking calculations o f HMGB1-GL complexes 
Molecular docking of glycyrrhizin on HMG Boxes was performed using the software 
HADDOCK 2.1_devel, which makes use of chemical-shift perturbation data to drive the 
docking while allowing various degrees of flexibility (Dominguez et al. 1998). The 
protocol follows a three-stage docking procedure which includes (1) randomization of 
orientations and rigid body minimization, (2) simulated annealing in torsion angle space, 
and (3) refinement in Cartesian space with explicit water. Residues showing chemical 
shifts larger than the average chemical shift difference plus one standard deviation were 
used to define active residues according to the HADDOCK definition, and were used as 
ambiguous interaction restraints (AIRs) (Dominguez et al., 2003). Residues that were 
close to the threshold, or with small (<50%) solvent-accessible surface areas, were not 
included in AIRs. Passive residues coincided with the region which was allowed to be 
flexible during the semiflexible simulated annealing step (Dominguez et al., 2003).
Intermolecular nOes, Ri/R2 values for each residues and 15N-[H RDCs values for 
each backbone amide bond were included as direct restraints in the calculations only in 
the final run: intermolecular NOEs were treated as unambiguous distance restraints, R7 
R2 values have been obtained from relaxation measurements using the diffusion
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anisotropy model of TENSOR2 (Dosset et al., 2000; Van Dijk et al., 2006) and RDCs 
have been transformed into intervector projection angle restraints (Meiler et al. 2000, 
Van Dijk et al., 2005). Optimized parameters for liquid simulation (OPLS) were used for 
the protein. The geometric coordinates and parameters for the ligand were calculated and 
optimized using the PRODRG server (Schuettenkolpf et al., 2004 ). During the rigid 
body docking, 2000 structures were calculated. The best 200 solutions in terms of 
intermolecular energies were selected for a semiflexible simulated annealing, followed 
by water refinement. The analysis of the simulations was performed applying in-house 
python and tel scripts. Root-mean-square deviations (RMSD) were calculated using the 
ProFit program (http://www.bioinf.org.uk/software/profit/). The fitting of the protein 
was performed on the residues belonging to the binding site using the McLachlan 
algorithm (McLachlan, 1982); the RMSD of glycyrrhizin was calculated only on the 
heavy atoms of the triterpene scaffold. The final RMSD matrix was then clustered using 
the algorithm described in Daura et al. (Daura et al. 1999), where a cluster is defined as 
an ensemble of at least two conformations displaying an RMSD smaller than 0.8 A. The 
final structures were clustered and scored using a combination of energy terms (total 
energy, intermolecular van der Waals and electrostatic energies, restraint energies).
2.4 Fluorescence Measurements
Experiments were performed on a Varian Eclipse instrument (Victoria, Australia) with 
excitation at 273 nm (slit width 5 nm) and emission at 325 nm (slit width 5 nm). The 
initial protein concentration was 3 |nM; after each ligand addition, the samples were left 
to equilibrate for 5 min. The ligand concentration at the end of the titration was 250 mM 
for Box B and 270 mM for Box A and HMGB1; the added ligand solution did not 
exceed 10% of the initial volume. At each data point, the protein concentration was 
corrected for the dilution due to ligand addition. All measurements were performed at 
25°C in 20 mM phosphate buffer (pH 7.2), 150 mM NaCl. Dissociation constants (Kd) 
for Box A and Box B were estimated considering a single-step binding process with an 
equimolar stoichiometry.
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The free ligand concentration in solution was considered approximately equal to 
the total concentration of added ligand. Experimental data were fitted by nonlinear 
regression (Xmgrace) to the equation:
F=F0— f 0 - f -  [z j (.2.8)
° [L0] + Kdl oJ
where F is the fluorescence intensity measured at each titration point, [L0] is the total 
ligand concentration added at each point, F0 is the initial fluorescence intensity of the 
unbound protein, and Foe corresponds to the fluorescence intensity of the bound final 
species.
Kd values for HMGB1 were estimated considering a mechanism in which two 
ligand molecules bind simultaneously and independently to Box A and Box B. 
Experimental binding curves have been fitted through the following equation:
F = F . , - F/ ' \  F,°-a[L.]+F. F”,8[L.] (2 9)[L.]+Km 1 J •" [£.]+*,„ L J (Z-V>
Notably, the calculated IQa and KdB were very similar; for this reason, we then used a 
model where K^a = = IQ.app and therefore the folowing equation has been used:
F = F a. n - 2 u Ff+I “- [Lo) V - W
\. q\  d , app
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3. The interaction of HMGB1 with Glycyrrhizin and 
Carbenoxolone
3.1 Summary
In order to characterize the binding of Glycyrrhizin (GL) to HMGB1 Box A and Box B, 
NMR and intrinsic triptophane fluorescence based titrations with GL were performed. 
NMR experiments also allowed the identification of the residues that are mostly 
perturbed by the presence of the ligand. Moreover, they both allowed the determination 
of the Kd of the process. Relaxation measurements have been performed in order to get a 
detailed description of the local and overall mobility of the protein upon binding. These 
data, taken all together, are the first step towards the atomic-level comprehension of the 
nature of the GL-HMGB1 binding. This part of the work contributes to the 
understanding of the molecular mechanism that regulates part of the cytokine activity of 
HMGB1 and identifies in GL a possible inhibitor of HMGB1 mediated cell migration 
and proliferation.
3.2 Results
3.2.1 Ligands and protein resonance assignment
NMR assignment of GL and carbenoxolone (CBNX) have been obtained starting from 
chemical shift datasets reported in literature and using the ID and 2D NMR experiments 
described in the previous chapter. As expected, the spectra of the two compounds 
appeared to be very similar due to the presence of a common triterpenic scaffold, and the 
glycosidic moiety of GL has been easily recognized in the spectra and assigned (see Fig. 
3.1). The two compounds displayed a different solubility: GL was soluble up to 50 mM 
in phosphate buffer 20 mM at pH 7.4, whereas CBNX had a lower solubility (less than 
10 mM) and was very unstable in solution (precipitation occurred within some days). 
The unassigned peaks were assigned to impurities generated during the process of 
chemical extraction of the compound from plants (Tianwei et al. 2002).
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Fig. 3.1 CBNX (a) and GL (b) 'H-13C HSQC spectra recorded in isotopic natural abundance. The signals 
due to 'H-13C coherences typical o f sugar rings are circled in red on the spectra of GL.
The sequential backbone assignment of full-length (FL) HMGB1 and its 
fragments Box A and Box B have been obtained using standard triple resonance
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experiments (Sattler et al, 1999) performed on the triple resonance spectra described in 
the previous chapter. The resonances have been deposited in the BMRB data bank 
(http://www.bmrb.wisc.edu) with accession numbers 15148 and 15149.
3.2.2 GL binds directly to HMGB1 Boxes.
Direct binding of GL to HMGB1 was probed using NMR chemical-shift differences 
(CSD), a highly sensitive tool for proving interactions and for mapping binding sites and 
detecting residues which directly interact with the ligand or that are indirectly affected 
by the association. Two-dimensional ^ -^ N  HSQC spectra of full-length 15N-labeled 
HMGB1 were recorded to monitor the changes in the ‘H-'5N chemical shifts of the 
backbone amide groups induced by successive additions of GL. A comparison of the 
spectra in the absence and presence of a 4-fold excess of GL is shown in Fig. 3.2a. The 
complex is in fast exchange on the chemical-shift timescale, as demonstrated by the 
monotonic trend of chemical shift displacements with respect to the amount of ligand 
added for each point of titration (an example is reported in Fig. 3.2b); this facilitated the 
assignments of the resonances in the complex, which were obtained following the cross 
peaks of HMGB 1 upon addition of increasing amounts of GL.
3.2.3 The ligand binding surface is identified by means of chemical shift mapping
To identify the interaction surface, the average chemical-shift changes between the free 
and the bound state were plotted versus the HMGB1 residue numbers (Fig. 3.3). Most of 
the protein residues do not experience relevant chemical-shift perturbation, indicating 
that GL does not alter the overall protein structure. The global preservation of the 
secondary structure was further confirmed by circular dichroism (CD) spectroscopy 
(Fig. 3.4). Resonances with significant CSD (deviating more than one standard deviation 
from the mean CSD) included residues Phel7, Gln20 (side-chain protons), Arg23, 
Gln25, Lys43, and Cys44 for Box A (Fig. 3.3a and 3.5) and Argl09, Ilel 12, Aspl23, 
and Alal25 for Box B (Fig. 3.3a and 3.6). No interactions were observed with the linker
63
108
1 1 3
15N
1 1 8
1 2 3
1 2 8
1 0  9  8  7
1H
b
1 10  
1 5 N
112
Fig. 3.2 (a) A com parison of the spectra o f I5N  labeled FL HM GB l in the absence (black) and presence 
(red) o f a 4-fold excess o f glycyrrhizin. (b) A selected region (G ln20 sidechain) o f H M GB l spectra during 
the titration w ith glycyrrhizin (0.5, l, l .5, 2, 3, 4 equivalents o f ligand). The starting and end points o f the 
titration are represented in black and red, respectively. The largest shifts w ere observed for the am ino 
group o f G ln20.
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Fig. 3.4 C ircu lar D ichroism  spectrum  o f free (continuous line) and GL bound (dashed line) HM GB1 FL 
protein.
region between the two boxes and the C terminal region. The individual peaks 
corresponding to the acidic tail residues could not be assigned because of high spectral 
overlap and exchange with the solvent (Knapp et al., 2004); however, these peaks did 
not shift upon addition of GL, excluding their involvement in the binding.
Previous structural studies have demonstrated that the two HMG boxes behave as 
rigid independent domains that do not interact with each other in the context of the full- 
length protein (Knapp et al., 2004); it was therefore verified whether GL binds similarly 
to the two individual HMG boxes (15N-labeled box A and box B) (Fig. 3.3b and 3.3c). 
Indeed, residues mostly affected by the presence of the ligand all clustered on the first 
two helices of both HMG boxes, and coincided with the residues showing high CSD in 
the full-length protein, indicating that the two Boxes actually behave in a non- 
cooperative way. Additional residues located on Helices 1 and 2 (His26, Lys42, Gin 107, 
Lysll3 , Glyl22, Glyl29, Metl33) were more affected in the isolated domains than 
within the entire protein. This effect might be due to a slightly different orientation of 
the ligand, or to small structural differences of the entire protein when compared to the
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Fig. 3.5 GL b inding site o f  Box A. R esidues that have been characterized by the biggest d isplacem ent in 
C SD  (17, 20, 23, 25, 43 and 44) are highlighted in red. C artoon (a) and surface (b) representations are 
reported. The protein  in (b) has been slightly reoriented in order to show  alm ost com pletely the binding 
surface.
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Fig. 3.6 GL binding site o f Box B. R esidues that have been characterized by the largest d isplacem ent in 
CSD  (109, 112, 123, 125) are highlighted in red. Cartoon (a) and surface (b) representations are reported. 
The protein in (b) has been slightly  reoriented in order to show  alm ost com pletely the binding surface.
isolated domains. On both HMG boxes (whether in HMGB 1 or in isolation), the binding 
site is located at the crux of the typical L-shape fold, which has a small solvent-exposed 
hydrophobic surface suitable for favorable van der W aals interactions with the triterpene
68
scaffold of GL (Fig. 3.5 and 3.6). Interestingly, in the upfield region of the 
monodimensional proton spectrum of both HMGB1 and Box A, variations in chemical 
shifts are also observed for the well-resolved [H methyl resonances of Vall9 and Val35, 
located on Helices 1 and 2 of box A, further suggesting an involvement of this region in 
the binding (Fig. 3.7). The titration experiments also indicate that Helix 3 is not involved 
in the binding. We repeated the titrations with carbenoxolone: in the case of Box A, we 
found that the highest chemical-shift perturbations of the backbone ‘H and 15N weretrans 
again located on the first two helices, as observed for GL (Fig. 3.8). Unfortunately, the 
spectra for Box B and the full-length protein at higher carbenoxolone concentrations 
were of low quality, and showed evidence of aggregation. This suggests that the 
triterpenic moiety of the ligands drives the binding, whereas the glycosidic moiety of GL 
contributes to its greater solubility with respect to carbenoxolone: this can explain also 
the partially different solubility of the complexes in molar excess of the ligand.
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Fig. 3.7 Upfield region o f ‘H monodimensional spectra of Box A during the titration with glycyrrhizin (0, 
1, 2, 3, 4 equivalents of ligand). The resonances corresponding to the methyls of V all9 (*) and Val35 (°) 
are marked.
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3.2.4 Influence o f the binding on the protein diffusional dynamics.
T1? T2 and heteronuclear NOE values for free and bound Box A and for free and bound 
Box B are reported respectively in Fig. 3.9 and in Fig. 3.10. Average values of T,, T2 
and heteronuclear NOE have been computed for helical regions and are reported in 
Table 3.1, together with correlation times xc that have been obtained from T, and T2 
using the empirical relationship of equation 2.3 (see Materials and Methods). In the table 
the residues that undergo large, slow and anisotropic motions are reported, together with 
the ones that are very flexible in the ns timescale and display a low (less than 0.6) value 
of heteronuclear NOE.
xc values for Box A and Box B reported in table 3.1 are very similar as expected
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Fig. 3.9 Ti(a), T 2 (b) and heteronuclear N O E (c) o f Box A (black) and o f Box A -G L  com plex ( r e d ) .
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System Ha T,b T2b hetNOE Tcb Excl. hetNOEc Excl.
t 2
BoxA
HI 820 + 80 68 + 9 0.71+0.10
10.8 + 
0.2
7, 9, 11,20, 25 
30-36, 46, 52, 54, 
73-89
none
H2 811+72 65 + 7 0.68 + 0.09
H3 934 + 70 58 + 6 0.71+0.10
BoxB
HI 899 + 101 75 + 10 0.72 + 0.11
10.0 + 
0.1
108, 115, 119, 
127, 132, 136, 
141, 148, 
158-175
148
H2 805 + 81 84+10 0.73 + 0.08
H3 953 ± 75 69 + 12 0.71+0.15
BoxA+
GL
HI 909 + 74 53 + 4 0.73 + 0.05
11.7 + 
0.5
7, 9, 10, 30-36, 
50, 52, 77-89
23,47,6
1,64
H2 905 + 140 48 + 1 0 0.69 + 0.10
H3 969 + 54 54 + 4 0.71+0.18
BoxB+
GL
HI 892 + 120 65 + 29 0.76 + 0.08
10.3 + 
0.4
115, 116, 137, 
151-154, 164-175
none
H2 810+110 86 + 31 0.79 + 0.11
H3 967 + 56 76 + 29 0.69 + 0.13
a. Box A: H elix l, 13-27; Helix2, 39-52; Helix3, 55-72.
B oxB : H elix l, 99-117; Helix2, 120-135; Helix3, 137-158.
b. Ti and T2 are expressed in ms; zc is expressed in ns .
c. Residues whose heteronuclear N O E  have been excluded. Exclusion princip les are explained in detail in 
the M aterials and M ethods section.
Table 3.1 Ti, T2 and heteronuclear NOE values, correlation times and residues not included in the data 
analysis (i.e., excluded residues) for the extraction of diffusive models due to excessive large motions.
from the overall similarity of the domains shape and fold, i.e .  10.8 ns for Box A and 10 
ns for Box B respectively. These values are in good agreement with the ones previously 
determined (Laue et al 1993). The values of xc for the complexes are very similar to the 
ones of the free proteins, i.e. 11.7 ns and 10.3 ns for Box A-GL and Box B-GL 
respectively. The variation of t c is at least 10% of the free protein value, as expected
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from the small size of the ligand that does not alter significantly the hydrodynamic 
radius of the protein. These values also indicate that the protein is still monomeric in 
solution after complexation.
The three main diffusional axis in Cartesian space Dx, Dy and Dz are reported in 
Fig. 3.11, and their values are reported in Table 3.2. The formation of the complex 
between Box A and GL alters the overall shape of the diffusion tensor with respect to 
free protein (see Table 3.2): despite the persistence of an oblate character, it assumes a 
more spherical shape (Fig. 3.11b) due to the very close values of the three axes. Box B -  
GL complex diffusion tensor does not differ significantly from the one of the free Box 
B: despite a formal change in the symmetry of the ellipsoid, the values of Dx and Dy for 
the complex are similar and are also very close to the ones of the free protein within 
fitting errors.
3.2.5 Changes o f internal Box A backbone mobility upon binding is monitored by 15N  
spin relaxation
Relaxation data of both free and bound Box A display homogeneity in the values of T2 
( <T2> ~ 62 ±10 ms) and of heteronuclear NOE ( <hetNOE> ~ 0.7 ± 0.1) excluding 
flexible regions, indicating that the secondary structure elements of the protein are not 
heavily perturbed by the binding of GL.
Low values of heteronuclear NOE (< 0.5) of the loop comprised between Hehx 1 
and Helix 2 indicate high mobility in the nanosecond timescale for these regions. The 
comparison of the differences between heteronuclear NOE datasets of the protein and of 
the complex reveals that the local dynamics for the free and bound protein in the ns 
timescale are very similar, i.e. differences between values for single residues are never 
larger than ±0.1. Also S2 values (Fig. 3.12a) extracted by means of the Lipari-Szabo 
formalism reveal this aspect: the differences of S2 between Box A-GL and Box A 
(reported in Fig. 3.13) are never higher than ±0.1 revealing no changes in local fast 
motions upon binding. Moreover, no relevant trends of S2 or heteronuclear NOE 
variations can be detected as a function of secondary structure elements.
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System Model3 d f t Dxc D clSy A c
Box A Asymm. 56 + 21 43 + 5 -40 + 5 0.10 + 
0.01
0.13 + 
0.01
0.23 + 
0.02
BoxB Ax.Simm. -88 + 6 -24 + 6 -24 + 6 0.13 + 
0.00
0.13 + 
0.00
0.23 + 
0.01
BoxA+GL Asymm. 31 ±37 71 + 28 -66 ± 20 0.12 + 
0.07
0.13 + 
0.01
0.16 + 
0.01
BoxB+GL Asymm. -83 + 32 -56 + 3 -32 + 4 0.12 + 
0.08
0.13 ± 
0.06
0.26 + 
0.01
a. In the axially symmetric model Dz =  Du, Dx = Dy =  Dr, J3 = y= (f), a = 6
b. Degrees
c. 100 X  MHz
Table 3.2 Diffusive models and relative angular parameters and axis magnitude
T2 values for the bound protein are lower than in the free form (with the exception 
of C and N termini) in the region comprising residues 10 and 54: in particular, this 
aspect can be observed for residues ranging from 29 to 40 that comprise the N terminal 
part of Helix 1, the C terminal part of Helix 2 and a flexible loop (Fig. 3.9). This region 
of the protein roughly corresponds to the set of residues whose chemical shift is mostly 
perturbed upon binding. T2 variations are reported in Fig. 3.14: the change of values of 
T2 can be usually related to chemical exchange, hence this graph suggests that the 
relaxation of 15N spin in this region reflects the binding kinetics of the ligand. In this 
sense, T2 values of Helices 1 and 2 are perturbed by the presence of the ligands: the 
greatest variations of T2 are reported in the loop region, suggesting that its slow motion 
is enhanced by the binding. This result is compatible with the absence of great variations 
in heteronuclear NOE between the complexed form and the free form of Box A, 
providing an indication that only slow motions (milliseconds time scale) are influenced 
by the binding.
Kex parameters have been extracted using the Lipari-Szabo model and they are
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cFig. 3.11 Ellipsoidal representation  o f diffusion tensors com puted from  T, and T 2 data for Box A (a), Box 
A -G L  (b), Box B (c) and Box B -G L  (d). The center o f  the axes is located in the centre o f m ass o f the 
protein. The dots reported on the surface o f  the ellipsoids are representative for the error distribution o f the 
D , Dy and Dx representation  com puted according to the statistical procedure described in the M aterials and 
M ethods section.
reported in Fig. 3.12b. The free protein displays Kex components that are quite spread 
over the whole structure, whereas upon binding the Kex components are located on 
Helices 1 and 2 and they identify the same binding site previously identified though 
chemical shift mapping. The presence of exchange contributions is also evidenced by the 
increased linewidths of peaks corresponding to methyl groups of residues 15 (Helix 1) 
and 35 (Helix 2) in the ID  spectrum reported in Fig. 3.7. Residues 23 and 47 exhibit an 
anomalous T2 (i.e., too low to exclude anisotropic motions contributions, see Table 3.1) 
that indicates the presence of anisotropic motion that can lead to an overestimation of
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Fig. 3.12 L ipari Szabo S2 (a) and (b) param eters extracted from the analysis o f relaxation data o f  free 
(black) and G L bound (red) Box A.
the proper exchange contribution. Residues 61 and 62, located on Helix 3, exhibit an 
exchange component: this can be partially explained by the contact with the residues 
belonging to GL binding site and located on Helix 1 and Helix 2.
Interestingly, the free Box A dynamics reveals the presence of exchange 
components in the C terminal region which could be related to an unstable helical
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Fig. 3.13 Histogram representation of the difference between S2 values of the bound and the free form of 
Box A.
folding of the residues between 68 and 75. This is in good agreement with REMD 
calculations (see Materials and Methods section) performed on free proteins that for this 
region display a quite high Coe RMSF (Fig. 3.15b). This information complements the 
description of a local helical fold in this region suggested by the deposited PDB 
structure and is in good agreement with the Ccc-RMSF computed on the bundle of 
structures of Box A (see Fig. 3.15a). Taken together, these data suggest that, with 
respect to the remaining part of the protein, in this region the helical motifs breath 
between different conformations due to a decreased structural stability. The timescale of 
REMD simulations is roughly 80 ns distributed over all the replicas: the agreement 
between this timescale and the one (i.e., ms) represented by a bundle of structure is quite 
surprising, but it can indicate that the essential motions that govern exchange 
contributions are well represented also by motions that take place in the high
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Fig. 3.14 H istogram  representation o f the difference betw een T? values o f the bound and the free form  o f 
B ox A. (a). T he residues are reported on the structure in red (b).
variation o f S2 ( > 0.2), confirming that for Box B motions in the ns timescale are 
perturbed by the binding of GL.
nanosecond timescale and that well represent the overall correlation time of the protein.
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Fig. 3.15 C a  R M SF o f  free B ox A com puted on the deposited bundle o f structures 1AAB (black) and 
from  a REM D  sim ulation perform ed as described in M aterials and M ethods section (red).
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Fig. 3.16 H istogram  representation  o f the difference betw een heteronuclear NOE  values o f the bound and 
the free form  o f  Box B.
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3.2.6 Changes o f internal Box B backbone mobility upon binding is monitored by 15N  
spin relaxation
As shown in Fig. 3.9c and 3.10c, average heteronuclear NOE values of Box B and of 
Box A are very similar ( ~ 0.7 , see Table 3.1). Upon binding, as reported in the 
histogram of Fig. 3.16, all the values change and the variation in many cases is quite 
high, indicating that the local dynamics sampled on the nanosecond is changed by the 
binding The average variation of hetNOE values is positive: this suggests that GL 
rigidifies the fast (ps-ns) motions of Box B upon binding. This result is also partially 
reflected in the DS2 values displayed in Fig. 3.18 (3.17 reports the S2 and Kex values 
obtained by Lipari-Szabo analysis of relaxation data): the plot reported suggests that 
residues 101, 109 and 122 are the ones whose ns dynamics is mostly influenced by the 
binding and that loose their conformational entropy.
T2 values for the free Box B are almost constant (T2, avg ~ 70ms) in the structured 
regions, with the second helix having T2 values slightly higher than the ones for the 
Helix 1 and 3. Upon binding, the T2 values mostly perturbed are the ones of the residues 
between 105 and 138, that corresponds to half of the Helix 1 and the complete Helix 2 
(see Fig. 3.17c), that fits well with the binding site for GL identified by chemical shift 
mapping. Similarly to Box A, the T2 values are lowered on average and there are some 
outliers with respect to the overall trend (i.e., T2 higher than the average) mainly located 
on Helix 2. Kex obtained for the free and bound state of Box B are reported in Fig. 3.17. 
The free protein reveals, like Box A, a few residues that could be fitted according to the 
Lipari-Szabo model using a Kex component. These residues are spread over the entire 
sequence: when GL complexes Box B exchange components can be identified only on 
the Helices 1 and 2 and they are not present on Helix 3. Noteworthy, the slowest term is 
associated to PhelOl: this observation is in good agreement with the direct contact with 
GL evidenced by 2D X-filtered NOESY experiments (see further). Moreover, residues 
123 and 125 are among the ones whose chemical shift is displaced mostly by ligand 
binding. Taken together these three residues identify the site that displays the greatest 
variation of S2 (> 0.2), confirming that for Box B motions in the ns timescale are 
perturbed by the binding of GL.
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Fig. 3.18 Histogram representation of the difference between S2 values of the bound and the free form of 
Box B.
3.2.7 Determination o f Kd by NMR and fluorescence
Dissociation constants were estimated by monitoring the change of individual 
resonance chemical shifts of the single boxes as a function of ligand concentration. Plots 
of the chemical-shift changes of two representative residues for box A (R23) and box B 
(R109) as a function of ligand concentration are shown in Fig. 3.19 Assuming a simple 
binary interaction between single boxes and GL, we derived Kd values of 103 + 25 pM 
and 87 + 35 pM for box A and box B, respectively. Because of the low quality of the 
NMR spectra of the full-length protein in the presence of GL at stoichiometric ratios 
higher than 1:4 (HMGBLGL), we could not follow the NMR signals up to saturation to 
obtain a reliable estimate of the binding constants. We investigated whether intrinsic 
fluorescence could be used to monitor the interaction of HMGB1 with GL (Fig. 3.20). 
Two conserved tryptophans (Trp48 and Trpl32 in box A and box B, respectively) are 
buried inside the hydrophobic core of the domain and do not belong to the proposed 
ligand binding site; as expected, no noticeable change in their fluorescence was observed 
(data not shown). Two tyrosine (Tyrl5 and Tyrl08 in Box A and Box B, respectively)
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Fig. 3.19 W eighted average o f the A rg23 (a) and A rg l0 9  (b) am ide 'H  and l5N  chem ical-shift changes as 
a function o f added g lycyrrhizin values have been com puted as reported in M aterials and M ethods. A  
sim ple binary interaction has been assum ed betw een single boxes and glycyrrhizin.
are close to the residues showing chemical-shift perturbations; tyrosine fluorescence 
decreases upon GL addition (3.20). Nonlinear least-squares fitting of the data yields 
dissociation constants of 170 + 3 pM for box A and 140 + 3 pM for box B, assuming a 
1:1 stoichiometry of isolated boxes and GL. The binding of GL to both HMG boxes,
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together with the structural independence of the boxes inside HMGB1, strongly suggest 
that the full-length protein has two independent binding sites for GL. We therefore fitted
100
0
OC
0
O
0
0
o
3
0 100 200 150 25050
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Fig. 3.20 Tyrosine fluorescence (excitation 273 nm , em ission 325 nm) was m easured (in arbitrary units; 
a.u.) upon titration o f  glycyrrhizin into solutions o f  Box A  (triangles), B ox B (circles), and FL -H M G B 1 
(squares). Sym bols correspond to experim ental data, w hereas continuous curves are derived according to 
equations described in the M aterials and M ethods section.
fluorescence data for the full-length protein assuming a 1:2 (HMGB1:GL) binding 
stoichiometry and two independent dissociation constants, KdA and KdB, for the 
binding site on box A and box B, respectively. Nonlinear least-squares fitting of the data 
did not yield two statistically different values for KdA and KdB but rather resulted in a 
common value of 156 ± 3 p,M. This value is similar to the value obtained for the single 
boxes, further suggesting that the binding of GL to the full-length protein is 
noncooperative and does not result in an improved binding affinity relative to single 
boxes. These results also suggest that the acidic tail does not interfere in the binding of 
GL to HMGB1.
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4. Structural models for the complexes
4.1 Summary
In the previous chapter binding of CBNX to Box A and of GL to Box A and to Box B 
was experimentally probed by chemical shift perturbation methods and by fluorescence 
spectroscopy: this procedure allowed a clear identification of the ligand binding sites on 
the surface of the protein. In the present chapter the problem of providing an atomic 
level description of the binding modes of CBNX and GL to the HMGB1 boxes is faced. 
Due to the quite high Kd values obtained for the complexes, protein-ligand NOE peaks 
obtained were insufficient for a complete structure determination performed adopting a 
standard approach {i.e. NOE derived distance based methods). This fact led us to adopt a 
combined computational and experimental approach for protein-ligand complex 
structure determination.
A hybrid quantum chemistry and molecular dynamics (MD) based method with 
back calculation and a posteriori confrontation with experimental data was adopted for 
CBNX: a density functional theory (DFT) approach was used for refining the ligand 
charges derived from a standard molecular mechanics force field and the whole complex 
dynamics was simulated using MD protocols.
A data driven docking procedure was instead adopted for GL, using all the 
available experimental data as restraints. This choice was driven by the poor reliability 
of available protein force fields for the treatment of sugar units in GL: even a quantum 
mechanics based strategy like the one adopted for CBNX would not have led to a 
reliable set of charges for sugar moieties, i.e. starting from a very approximate set of 
charges. Hence, using the whole set of data available from NMR experiments in order to 
get intermolecular restraints for protein-ligand docking, despite the great problems faced 
by this kind of algorithm, offered the more accurate and fastest solution available to the 
problem of determining the structure of the Box A-GL and of the Box B-GL complexes.
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4.2 Results
4.2.1 Experimental measurements on Box A-CBNX complex
STD measurements have been performed on all the systems previously described (see 
previous chapter), suggesting the proximity of the ligand methyls 12, 19, 24, 25, 26 and 
28 (see Materials and Methods, Fig. 1.1) to the surface of the protein in all the cases 
considered, confirming the importance of the triterpenic scaffold in the binding, as 
previously demonstrated. STD measurements performed on Box A-CBNX complex are 
reported in Fig. 4.1. This kind of experiment is usually performed with success on 
complexes formed by large proteins (>10kD) and flexible ligands, because this 
experimental condition ensures the optimal magnetization transfer from protein to 
ligand. In this way it is possible, in principle, to quantify the distance of ligand protons 
from the surface of the protein and to evaluate the kinetics of binding through the 
determination of kon and koff for single protons (Mayer and Meyer, 2000). In this case the 
rigidity of the triterpenic scaffold could bias the relative amount of transfer 
magnetization and consequently bias any quantitative evaluation of distances. However, 
it was possible to identify with good confidence the CBNX methyl groups that are in 
contact with the protein surface hence defining well the ligand-protein interaction 
surface.
In order to establish the protein-ligand contacts, X filtered NOESY 
measurements were performed (Breeze, 2003) adopting the co2 15N13C filtering scheme 
(Fig. 4.2) in order to identify the hydrogen atoms of the ligand along the direct 
dimension and the one of protein sidechains along the indirect one: protein signals were 
previously identified by means of and 15N edited HSQC-NOESY. In Fig.4.2 a portion of 
the X-filtered spectrum obtained for the complex Box A-CBNX is reported: peaks 
inside the box correspond to contacts between methyl and methylene GL protons and 
protons of protein aromatic sidechains of residues Tyrl5 and Phe37. This experiment 
allowed the identification of up to 10-15 intermolecular contacts, but the signal intensity 
and broadening (that depended presumably on different positions assumed by the ligand 
in the protein binding site) disallowed any precise evaluation of inter proton distances. 
Only qualitative evaluation on the distances involved was done and classified according
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to the intensities of signals (see further). The contacts between Box A and CBNX are 
reported in Table 4.1.
4.2.2 QRFF-MD simulation o f the BoxA -  CBNX complex
Using all the available experimental information about the protein-ligand interaction 
surface and ligand orientation (i.e., CSD, X-filtered NOESY and STD spectra) we 
attempted to place the ligand manually on the protein surface and also used 
AUTODOCK for an independent (unconstrained) docking. In both cases, we ended up 
with a configuration of the type illustrated in Fig. 4.3a in which the ligand is positioned 
on the surface of both Helix 1 and 2. This structure was equilibrated in explicit solvent
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NOE Assignment Signal Intensity
----------------- 8-------
Distance (A)
QRFF
6
Distance (A) 
Unrefined
Tyrl5,H8 -H 26 weak 5.6 ± 0.4 3.9 ±0.3
Tyrl5,H5 -H 28 weak 3.4 ± 0.4 3.8 ±0.5
Tyrl5,He -H 28 weak 3.0 ± 0.4 4.6 ± 0.6
Phe37,He -H 2 0 weak 6.0 ± 0.5 12.6 ±0.8
Phe37,H5 -H 2 4 weak 8.2 ±0.6 3.2 ± 0.4
Phe37,He -H 24 weak 6.5 ±0.5 3.6 ±0.5
Phe37,He -H 25 weak 8.8 ± 0.4 5.4 ±0.5
Phe37,H5 -H 26 strong 3.2 ±0.4 7.4 ± 0.4
Phe37,H£ -H 26 strong 2.9 ± 0.3 8.1 ±0.9
Phe37,H8 -H 27 weak 6.9 ±0.3 9.0 ± 0.4
Phe37,He -H 27 medium 7.4 ± 0.4 10.0 ±0.7
Phe37,H5 -H 28 medium 2.4 ±0.3 11.3 ±0.5
Phe37,He -H 28 medium 3.7 ±0.5 12.0 ±0.9
Phe37,He -H 3 4 weak 9.0 ± 1.1 14.9 ±0.8
Table 4.1 Observed NOEs, features (i.e., intensity) of the signals, and intemuclear distances obtained from 
r'6 averaging over the trajectories o f REMD simulations, based either on the unrefined force field or on the 
quantum-refined (QRFF) force field.
Complex Ambiguous Restraints Unambiguous Restraints
Box A-GL 17, 20, 23, 25, 26, 42, 43 15-H28, 37-H27, 37-H19
Box A-GL 107, 109, 113, 122, 123, 125, 129,133 102-H34, 102-H28, 101-H24
Table 4.2 List o f ambiguous and unambiguous restraints used for docking calculations for Box A-GL and 
Box B-G L complexes. Residues whose chemical shift was affected by the binding are reported as 
ambiguous restraints. The unambiguous restraints reported refer to NOEs arising from protein-ligand 
contacts, and are reported in the form of a residue sidechain proton (see text)- ligand proton contact.
using the GROMOS 453al FF (see Materials and Methods section) for 1 ns (region I). 
Subsequently, the QRFF based MD was used (i.e., standard topology file was replaced
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by the QRFF modified one) and the system was let free to evolve for 5 ns at room 
temperature. The time variation of the ligand-protein interaction energy is reported in 
Fig. 4.4 and clearly shows that after about 2 ns (region II) the system spontaneously 
found a more thermodynamically favored basin (DE = 75 + 12 kJ/mol). The analysis of 
the binding energy of the complex shows that the gain corresponding to the structural 
transition (from energy basin I to II) is larger for the electrostatic component (DE = 50 + 
10 kJ/mol) than for the dispersive term (DE = 25 + 5 kJ/mol). The separate energetic 
components are reported in Fig. 4.5.
Corresponding to the transition from the starting complex configuration to 
the final energetic equilibrium plateau (II), the complex underwent a substantial 
structural rearrangement, as reported in Fig. 4.3b, which illustrates the structure obtained 
from averaging over the configurations visited by the system during the final 2 ns of 
MD. At the transition (Fig. 4.4), the ligand reoriented itself almost perpendicularly to 
Helix 1, thus moving away from Helix 2: as expected, the structure of the ligand turned 
out to be rather rigid over this period, with a RMSD of 0.8 + 0.2 A (computed on the 
triterpenic scaffold of CBNX). This binding mode is consistent with chemical shift 
difference data upon binding (Fig. 3.8) due to the proximity of the ligand with the 
residues whose chemical shift was mostly perturbed by the binding.
The binding of CBNX and its rearrangement during the run do not alter 
the global conformation of the protein, as demonstrated by the relatively low C a RMSD 
(2.2 + 0.4 A) computed on structured portion of the protein (i.e., from residue 12 to 
residue 72) and by comparison of the Ramachandran plots of the two structure (Fig. 4.6) 
that ensures that no local structural distortions occurred during the ligand rearrangement 
on the surface of the protein. This finding is in total agreement with circular dichroism 
data (see Fig. 3.4). However, Helices orientation analysis reveals local modifications 
induced by the binding: the major change we observe pertains to the relative orientations 
of Helices 1 and 2 (Fig. 4.7), which change by up to ~ 20°. After the transition, the 
backbone remains rather rigid: the Ca RMSD of the backbone over the last 2 ns amounts 
to 1.1 +0.3 A.
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Fig. 4.3 Box A -C B N X  com plex structures at the beginning (a) and at the end o f the 5 ns M D  sim ulation. 
The structure reported in (a) is the one obtained through A utoD ock docking calculations.
92
. 5 0 -
g  -iso -
3 , *200 -
*350 *
-400
0 2 31 4
Time (ns)
Fig. 4.4 Total interaction potential energy of the protein-ligand system.
Several residues are involved in a hydrophobic contact with CBNX, in particular, 
Arg9, GlylO, L ysll, Metl2, Tyrl5, Alal6, Phe37 and Ser41 The structure is 
furthermore stabilized by the formation of a single hydrogen bond between Ser38 
sidechain hydroxyl and the carboxylic oxygen 034 of CBNX: this bond corresponds to a 
distance of 2.7 + 0.5 A but it has a lifetime of at most 50 ps (Fig. 4.8).
REMD simulations in NPT and NVT ensemble in the range 300-380K were 
performed in order to test the stability of the protein-ligand configuration found during 
the 5 ns MD simulation. The structure resulted to be very stable and a cluster analysis 
performed according to the minimum distance matrix method (Daura et al. 1999) 
revealed the presence of 22 ligand clusters with a cutoff of 0.1 nm that are shown in Fig. 
4.9. Moreover, the REMD trajectories analysis confirmed the data obtained by MD 
simulations. In addition, the analysis of the NPT REMD trajectories for the ligand- 
protein interaction energy in the range 300-400 K reveals quite surprisingly that its 
contribution to the specific heat Cp does not depend on temperature (Fig. 4.10) and only
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Fig. 4.5 Electrostatic (a) and dispersive (b) potential energy contributions to the overall protein-ligand 
interaction potential.
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Fig. 4.6 R am achandran plots o f  the starting (a) and final (b) protein configurations obtained from  the 5 ns 
M D sim ulations. The states reported correspond to the ones show n in Fig. F ig .4 .3a and Fig.4.3b 
respectively.
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Fig. 4.7 Superim position o f protein structures at the end (blue) and at the beginning o f the 5 ns 
sim ulation.
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Fig. 4.8 Length o f  hydrogen bond betw een H(3 o f Ser38 and 0 3 4  o f C B N X  m onitored during the 5 ns 
sim ulation.
Fig. 4.9 22 C luster structures for bound C BN X  extracted from  3000 fram es o f  N V T REM D  sim ulation. 
C lusters have been obtained using a 0.1 nm  cutoff and applying the linkage algorithm .
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Fig. 4.10 Protein-ligand potential interaction energy expressed in function o f  1/T for each replica in N PT  
ensem ble. The energy has been extracted averaging the values sam pled in the last 500ps o f sim ulation for 
each replica.
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Fig. 4.11 Tw o structures o f  B ox A  -  C B N X  com plex obtained sam pling the 5ns unrefined G RO M O S FF  
based sim ulation. The one reported in (a) differs from  the other in (b) due to the form ation o f three stable 
hydrogen bonds. The distances betw een donor (H b Ser38) and acceptor ( O i l  C BN X ) are show n for the 
tw o cases.In (b) the sidechain is also indicated.
at high temperature the energy distribution becomes scattered but never exhibiting a 
specific trend. This observation is fully consistent with the negligible contribution of 
directional H-bonds. In summary, the analysis of the Q R FF-M D  trajectories leads to the 
conclusion that several hydrophobic contacts drive the ligand-protein interaction and 
that the relevant characteristics of the ligand are its shape and its global charge 
distribution. Therefore these findings confirm that a quantum refinem ent of the FF was 
necessary in order to improve the parametrization of long-range electrostatic 
interactions, also preserving consistency with the van der W aals interaction parameters 
that are relevant for non directional interactions.
In order to provide a reference for the improvement gained by the usage of the 
quantum refined force field, also a 5 ns MD and a 60 ns REMD simulations with 
standard GROMOS force field were performed. W ithin a 5 ns MD run the ligand 
fluctuated essentially between two states (reported in Fig. 4.11) of almost comparable
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Fig. 4.12 Structures o f  the Box A -C B N X  com plex obtained by Q R FF (a) and G RO M O S (b) based 
sim ulations. Protein has been rendered by surface representation, ligands are represented in lines and 
hydrogen atom s that resulted to be in contact from  STD  experim ents have been reported using brow n 
spheres.
Fig. 4.13 C om plex final configuration obtained by R EM D  sim ulations adopting unrefined G RO M O S FF.
probability characterized by contacts with T yrl5 , A la l6  and F37 and by slightly 
different orientations. In the configuration reported in Fig. 4.11a (59% probability) the 
C l 1-011 carbonyl is directed towards the Helix 2 of the protein and three H-bonds were 
formed: a short one, 0 1 1-Ser41 (1.6 ± 0.1 A), and two longer ones, 0 32 -S er38  (2.5 ± 
0.9 A) and 034-P he37  (2.7 + 0.6 A), all with a lifetime on the order of 100 ps. In the 
other state (41% probability, see Fig. 4.1 lb), H-bonds were absent. Subsequent REMD 
search (60 ns) led essentially to stabilize the one reported in Fig. 4.1 la: the O l 1-Ser41 
bond was 1.7 + 0.1 A long with a lifetime up to 2.5 ns, whereas 032 -S er38  (2.1 ± 0.6 
A) and 034-P he37  (2.2 + 0.4 A) bonds had lifetimes up to 0.3 ns. In this sense, 
unrefined FF overestimates the directional forces and hence pushes the ligand towards 
the Helix 2 and does not allow ligand reorientation.
The protein interacting surface and the overall position of the triterpenic ligand 
scaffold obtained with the two methods have been compared with experimental data 
(CSD and STD). The structure of the complex obtained from QRFF based simulations
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displays excellent agreement with CSD (Fig. 4.3b) and STD (Fig. 4.12) data, whereas 
the GROMOS based complex structure (i.e., the one obtained by REMD simulations) is 
not fully consistent with these data (Fig. 4.13): in particular, M etl2 and Phel7 CSD 
remains partially unexplained and also some of the methyls identified by STD (12, 19, 
26). In order to further investigate the reliability of the obtained model, NOE peak 
intensities have been compared to proton-proton distances averaged on equilibrium 
configurations of the complex sampled from QRFF and GROMOS based simulations. 
Table 4.2 reports the results of distance calculations for the contacts (Neuhaus et al., 
2000) with the two aromatic rings of the Tyrl5 and Phe37 side-chains computed using 
an r 6 averaging (Zagrovic et al., 2006) and referring to averages over 8 replicas centered 
at 310 K for REMD simulations and to the last 2 ns for the 300 K MD simulations. 
Although the comparison can only be qualitative, global consistency between the 
experimental observations and the values derived from the QRFF trajectories can be 
seen, at least for strong and intermediate NOEs. Discrepancies are more significant 
when the trajectories are taken from the MD runs using the unrefined scheme: especially 
the contacts with Phe37, which appear to be very relevant, would be lost without 
quantum chemical refinement.
4.2.3 Experimental measurements on Box A-GL and Box B-GL complexes 
The same kind of X-filtered experiments previously described have been performed on 
Box A-GL and Box B-GL complexes in order to establish the protein-ligand contacts. 
Also in the present case up to 15 intermolecular contacts between HMGB1 boxes and 
GL have been found: the residues involved in these contacts were the aromatic residues 
located at the junction of the two arms of the L-shaped fold of Box A (Tyrl5 and Phe37) 
and of Box B (PhelOl and Phel02). Table 4.2 reports the contacts between the proteins 
and the ligand and how they have been used as ambiguous and unambiguous restraints.
In order to take into account for local protein distortion induced by the presence 
of the binding lH-I5N RDCs have been measured using cylinder shaped 6% acrylamide 
gels (see Materials and Methods). The values experimentally obtained for each 
backbone amide bond for both free and bound proteins are reported for Box A and for
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Box B in Fig. 4.14 and in Fig. 4.15 respectively.
4.2.4 Data driven docking calculations performed on Box A-GL and Box B-GLr 
complexes
Despite the chemical similarity between GL and CBNX, the application of QRFF 
methodology presented led us to unreliable results and also to several calculation 
failures probably due to a partial inconsistency of the novel force field. This can be 
largely explained by the very well documented difficulty in properly describing sugar 
rings in the most chemically reliable way adopting classical and semiclassical schemes 
(Woods et al., 1995; Guvench et al., 2008). The refinement of an existing force field was 
behind the purpose of the present work.
We therefore adopted the HADDOCK strategy (Dominguez et al., 2003), a 
recent but well-established procedure which uses experimental chemical-shift data to 
drive molecular docking, both of proteins and of small molecules (Schieborr et al., 
2005). In order to obtain an atomic level model of Box A-GL and Box B-GL complexes 
all the experimental data obtained for these systems have been used, i.e. chemical shift 
differences between free and bound proteins (see Chapter 1), intermolecular NOEs, 
protein RDCs and relaxation data (see Chapter 1).
The usage of RDCs in HADDOCK allowed in both cases the generation of an 
ensamble of protein structures within the complexes whose backbones are extremely 
well superimposed, leading to an average C a - RSMD of 0.41 A for Box A (min 0.19 
A; max 0.73 A) and of 0.81 A for Box B (min 0.28 A; max 0.63 A). Q factors computed 
for Box A and Box B, excluding the unstructured regions, are 0.34 and 0.41 
respectively,
HADDOCK docking procedures generated an ensemble of 2000 structures, from 
which only the best 200 (i.e., according to a minimum energy criterion) were extracted 
and refined in an explicit water model. These last 200 were clustered according to 
geometrical superimposition of ligand (see Materials and Methods) with a cut off of 3 A 
and a minimum number of 4 structures for bundle (in order to ensure a statistical 
significance). Clusters populations are reported in Fig. 4.16 and Fig. 4.17. In both cases
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Fig. 4.14 R esidual d ipolar copling values for am ide bond for free (black) and bound (red) Box A.
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Fig. 4.15 Residual dipolar coupling values for am ide bond for free (black) and bound (red) B ox B.
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Fig. 4.16 HADDOCK clusters population for Box A-G L complex.
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Fig. 4.17 HADDOCK clusters population for Box B-G L complex.
a similar number of clusters have been obtained (8 for Box A, 9 for Box B). The overall 
number of structures that were successfully clustered is similar (70 for Box A, 72 for
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Box B) and the population distributions only slightly differ.
Structures and clusters have been ranked adopting both an energetic and 
statistical criterion. Clusters have been considered representative for the “true” structure 
when displayed the lowest interaction energy between the protein and the ligand, i.e. 
they had the lowest non bonded interaction energy. Moreover, when the energetic 
criterion was too stringent (i.e., the clusters energies were too close to each other) to 
sharply decide between two ensembles of structures, due to the data driven nature of the 
present methodology, the most populated ensemble was considered to be the most 
reliable. Fig. 4.18, 4.19 and 4.20 report respectively the non bonded interactions, the 
Van der Waals and the Coulombic interactions for Box A-GL and for Box B-GL 
complexes. According to the choice criterion exposed above, cluster 1 has been 
considered representative of the binding mode of Box A due to the lowest non bonded 
energy term and the highest population, whereas cluster 7 has been chosen for Box B - 
GL complex despite the low population but due to the most favorable non bonded 
energetic term among the other clusters. Moreover, the two clusters considered 
displayed no significative deviation from unambiguous and ambiguous restraints, from 
experimental R2/Ri ratios (see Materials and Methods) and from experimental RDCs: the 
statistics about violations are reported in Table 4.3. The four best structures (i.e., 
according to the energetics of the complex) for each cluster are reported in Fig. 4.21: in 
both cases the region of interaction is well defined and the bad superimposition of sugar 
moiety of GL is in good agreement with experimental data that indicate that only the 
triterpenic moiety is relevant for the binding.
Data driven docking calculations led to a model for Box A-GL complex 
comparable to the one identified by means of QRFF methodology and reported in Fig. 
4.22: the triterpenic scaffold of GL accommodates in the junction of the two arms in a 
very similar way to the binding mode of CBNX to Box A and establishing favorable 
Van der Waals interactions with Ala 16, Tyrl5, Vall9 and Phe37 and sugars pointing 
away from the Helices 1 and 2. Moreover, the model predicts the formation of a strong 
hydrogen bond (2 A long) between the carboxylate of GL and the hydroxyl group of 
Ser38, that seems to be the only stable and directional interaction of the complex.
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Fig. 4.18 Non bonded interactions energy of Box A-GL (a) and Box B-GL (b) complexes as a function of 
the cluster number.
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Fig. 4.19 Van der Waals interactions energy of Box A-G L (a) and Box B-GL (b) complexes as a function 
of the cluster number.
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Fig. 4.21 B est 4 structures (i.e., ranked according to the non bonded energy term ) o f the clusters w ith 
low est non bonded interactions energy for Box A (a) and Box B (b) com plexes w ith GL.
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Fig. 4.22 B inding site o f  GL fo r the Box A -G L  com plex, (a) residues w ith the greatest chem ical shift 
d isplacem ent upon binding are reported in red in ribbons representation; the residues with whom  N O E 
contacts have been detected (T y rl5  and Phe37) are reported in green; Ser38 and the bond form ed by its 
sidechain and carboxylic group o f  GL are reported, (b) Ser38 and the bond form ed by its sidechain and 
G L are reported for sake o f  clarity.
1 10
Fig. 4.23 B inding site o f  GL fo r the Box B -G L  com plex, (a) residues w ith the greatest chem ical shift 
displacem ent upon binding are reported in red in ribbons representation; the residues with whom  NOE 
contacts have been detected (PhelO l and P he l02 ) are reported in green ; A rg l0 9  and the bond form ed by 
its sidechain and carboxylic group o f G L are reported, (b) R esidues that form  the hydrophobic stretch that 
accom m odates the ligand are evidenced in yellow  through a Van der W aals representation; A rg l0 9  and 
the bond form ed by its sidechain and GL are reported for sake o f  clarity.
I l l
The HADDOCK calculations suggest similar interactions between Box B and 
GL (Fig. 4.23): the ligand accommodates on the shallow concave surface formed by the 
two arms of the HMG box, creating favorable hydrophobic interactions between its 
triterpenic scaffold and the side chains of PhelOl,Phe 102, lie 121, and Alal25. Similarly 
to Box A, the model predicts a single directional interaction (an intermediate hydrogen 
bond, 2.5 A long) between the carboxylic group of the ligand and the guanidinium 
moiety of Argl09. Also for Box B the glycosidic moiety of GL points away from 
Helices and from the binding site.
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5. Discussion
5.1 Summary
In the last years the problem of finding novel drugs against inflammation has become 
central, due to the detrimental effects of known antiinflammatory drugs, whether they 
are steroidal (SAIDs) or nonsteroidal (NSAIDs) molecules (Rhen et al., 2005). One 
solution to this scientific and clinical problem is the rediscovery of old drugs that 
originally were not used against inflammation, like thalidomide, whose side effects are 
known and well documented. In this perspective, some natural drugs are under 
investigation, especially molecules whose interactions with the NF-kappaB pathway are 
documented (like curcumin or epigallocatechin 3 gallate) (Maroon et al., 2006). 
However, in the last years the main focus of a large part of the scientific community is 
the identification of pathways and proteins involved in inflammation processes that are 
new with respect to the “traditional” inflammation mechanisms (Chong et al., 2007). A 
few years ago it was demonstrated that High Mobility Group Box 1 protein (HMGB1) 
acts both as an architectural chromatin protein and as a cytokine when released in the 
extracellular space both actively or during cell necrosis (Muller et al., 2001; Yang et al., 
2005), mediating proinflammatory processes like cell migration and proliferation, hence 
becoming a promising target for antiinflammatory drugs. Recently, it has been 
demonstrated that glycyrrhizin (GL), a naturally occurring triterpenic drug widely used 
in clinical trials against SARS and Hepatitis C virus (Coon et al., 2004; Fuji et al., 2004), 
is able to inhibit HMGB1 induced cell migration and proliferation (see Preliminary 
results) and to reduce the effect of Hepatitis C in animal models in which it was 
demonstrated that HMGB1 plays a pivotal role (Sitia et al., 2007). In this sense, the 
analysis of the physical-chemical determinants of protein-ligand binding is a crucial step 
for obtaining a full comprehension of the molecular mechanism that regulates the 
influence of GL on the HMGB1 activity. Moreover, the atomic level description of this 
interaction is an essential step for any further HMGB1-GL interaction based drug 
development process.
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In the present work we addressed the question whether GL interacts directly with 
HMGB1 and which role single HMGB1 Boxes have in the ligand binding: moreover, 
adopting different computational techniques we have described the binding mode of GL 
and of its analogue carbenoxolone (CBNX) to HMGB1 Boxes at atomic level, partially 
elucidating the atomic level determinants of anti-inflammatory properties of GL and 
providing a first step towards the design of new derivatives with improved HMGB1- 
binding properties.
5.2 General features of the HMGB1-GL/HMGB1-CBNX binding
Through fluorescence and NMR spectroscopy we demonstrated that GL binds to both 
Boxes with a similar Kd (-150 pm). The Boxes in the full length protein are able to bind 
ligands independently (with a 1:1 stoichiometry) and in a non cooperative way. 
Fluorescence and NMR based titration are techniques that work at different 
concentrations of protein (respectively in the micromolar and in the millimolar or high 
micromolar range), hence the agreement between the Kd values indicate that the drug- 
protein binding process is not concentration dependent.
As indicated by circular dichroism spectra, the binding of GL to HMGB1 Boxes 
does not alter the secondary structure of Box A nor of Box B. Moreover, the protein 
ligand binding is driven by the interaction between the polipeptide chain and the 
triterpenic scaffold of GL, as suggested by experiments performed with the GL analogue 
CBNX, that lacks the glycosidic moiety. This interaction pattern is reminiscent of the 
one described for DNA polymerase (3: in this case as well, carbenoxolone binds on the 
surface of the protein, optimizing the interactions with the hydrophobic cleft formed by 
two helices (Hu et al., 2004).
The diffusion mode of the complexes remains unaltered upon binding as 
demonstrated by the very small variations of t c between the free and the bound forms of 
both Box A and Box B. These data also indicate that the complex formation does not 
modify the monomeric state of the target protein.
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5.3 Indentification of HMGB1 binding site for GL/CBNX
By chemical shift perturbation experiments we identified the GL binding site which is 
localized at the junction of the two arms of the classical L-shape fold of both HMG 
Boxes, i.e. only Helices 1 and 2 are directly involved in the binding, whereas Helix 3 is 
untouched by ligand binding. The same region displays a relevant decrease of 15N T2 
values upon binding, confirming the chemical shift perturbation data and suggesting that 
the binding site of GL becomes more rigid upon binding on a timescale that goes from 
higher nanosecond (comparable to the correlation time) to millisecond timescale 
(comparable to intrinsic spin relaxation timescale). Notably, the binding sites for 
glycyrrhizin on the HMG Boxes partially overlap with the DNA binding sites, shielding 
residues such as Arg23, which is well known to be crucial for DNA binding (Ohndorf et 
al., 1999). The modest effect of glycyrrhizin on the intranuclear function of HMGB1 is 
in agreement with the absence of cytotoxicity even at high glycyrrhizin concentrations 
and with the good pharmacological tolerability of glycyrrhizin in rodents and humans 
(Ploeger et al., 2001). This is possibly due to the vast difference in the affinity of 
glycyrrhizin and distorted DNA for HMGB1 (on the order of 100 pM and 10 nM, 
respectively) (Bianchi et al., 1992). Interestingly, glycyrrhizin does not cause the release 
of HMGB1 from apoptotic chromatin, implying that it will not produce paradoxical 
proinflammatory responses to apoptotic cells.
5.4 The influence of GL binding on the HMGB1 backbone mobility
The “model free” analysis of relaxation data allowed the determination of Kex values for 
some residues and the consequent evaluation of exchange contributions for each residues 
where present, i.e. the exchange of amide protons between environments due to 
conformational local transitions. Upon binding, the backbone dynamics of residues 
Ala 19, Arg23, Lys27, Asn36, Ser38 and Arg47 located on Box A display exchange 
contributions (Fig. 5.1a), whereas residues Glu73, Met74 and Thr76 upon binding loose 
their exchange contributions to overall dynamics on a slow (ms) timescale. The residues 
located on Helix 1 and 2 can be seen as probes of binding kinetics, i.e. amide backbone
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protons exchange between bound and free states at a frequency (see Fig. 3.12) of 5-10 
Hz. The loss of exchange contributions for residues located on the C terminal part of 
Helix 3, even though they are not involved in direct contact with the ligand, indicates 
that the binding of GL influences all the protein dynamics and perturbs the 
conformational sampling of residues that are not located in the binding site. The same 
behavior has recently been observed in Heat Shock Protein 90 (Colombo et al., 2008) 
where ligand binding is reflected by enhancement or freezing of protein motions also 
distant from the binding site. In the cited reference, the authors advanced the hypothesis 
that a protein can exhibit differences in the local dynamics as a function of a binding 
partner, and that molecular recognition is to some extent compatible with well 
determined and possible motions. In this sense, our findings suggest that GL binding 
freezes slow motions of the C terminal part of Box A, that becomes more tethered and 
hence displays a different accessibility (with respect to free protein) towards other 
proteins or ligands: in principle this could allow interactions that are mediated by GL 
binding even without a direct contact with the small molecule.
In the Box B-GL complex the dynamics perturbation is highly localized on Helix 
2 only (Ke*is increased upon binding, with respect to protein only, for residues Leul03, 
Hisll6, Vall24 ans Leul28, Fig.5.1b), indicating that this helix is more sensitive to the 
presence of the ligand. Interestingly, no long range effect is observed like in the case of 
Box A; residues Alal36, Tyrl43 and Lysl46 no longer display exchange in the bound 
state, indicating that the interhelical loop region is stabilized by the binding. Moreover, 
fast motions in Box B are at least partially blocked by the binding, as indicated by an 
average increase of S'2 parameter through the whole sequence.
5.5 Atomic level description of the binding
The model structures of the complexes formed by GL and HMGB1 Boxes, obtained 
adopting a data driven docking procedure as implemented in HADDOCK, were able to 
provide an atomic level description of the binding incorporating all the experimental 
data in structure calculations and refinement. HADDOCK is able to generate many 
structures (ensembles) starting from different sets of experimental data; however, a
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complex structure generated adopting this procedure cannot be considered reliable as a 
standalone structure, but within an ensemble of structures that share one or more 
common features according to a clustering criterion. In the present study the criterion 
adopted was the one of the lowest non bonded average interaction energy, followed by 
cluster population in case of similar cluster energies. For all the GL complexes studied, 
the cluster with the lowest non bonded energy displays almost the same non bonded 
average energy (-22 kcal/mol and -25 kcal/mol for Box A-GL and Box B-GL 
respectively): the most energetically favorable cluster for Box A coincided with the most 
populated one ( cluster 1), whereas Box B-GL most favorable cluster is one of the less 
populated (cluster 7, see Fig.4.17 and 4.18). However, the first ranked and most populated 
cluster obtained for Box B-GL complex has a configuration (Fig. 5.2) very similar to the 
one displayed for the cluster that has the most favorable non bonded interaction energy 
and that has been chosen as representative of the binding mode of GL to Box B (Fig. 
4.21b) despite a reduced population. This information together with the energy profile of 
clusters energies (Fig. 4.18), indicates that the GL binding region presents a quite flat 
energy landscape, that allows the accommodation of slightly different configurations of 
the ligand with a similar energetic content: among them, some configurations are more 
populated and slightly more favorable than others. In this sense the result of the 
presented docking calculations can be statistically interpreted as representative of the 
mobility of the ligand within the binding site. This interpretation recalls the principle of 
a drug discovery techniques that has recently defined as 4D QSAR (Lukacova et al., 
2004), where the binding mode of a ligand takes into account the binding site of a 
protein, the 3D structure of the ligand and the local mobility of the ligand itself within 
the binding site: in this way, not only the classical Hansch lock-and-key analogy is used 
(Hansch et al., 1964), but also local geometry variations are taken into account for 
exploring local minima.
For both Box A and B the ligand accommodates in the same region of the 
protein, that corresponds to the HMGB1 DNA binding region (Ohndorf et al. 1999; Read 
et al. 1993; Weir et al., 1993) adopting a different orientation. Single specific 
electrostatic interactions between the carboxyl group of the triterpenic scaffold of the
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Fig. 5.2 B est 4 solutions (accoding to non bonded energy o f  the com plex) from  the cluster 1 obtained 
adopting the H A D D O C K  strategy for the Box B -G L com plex. C om parison has to be done w ith F ig .4 .2 lb , 
that reports the m ost energetically representative but less populated cluster 7.
ligand (034) and the sidechain of a single residue can be observed: the interacting 
residue is located on the Helix 1 (Ser38) and on the Helix 2 (A rgl09) for Box A and Box 
B respectively. The different ligand orientations obtained suggest that, although Box A 
and B share a similar fold, the region that is able to perform molecular recognition has 
different chemical features in the two domains, allowing different binding mode of the 
same ligand. This hypothesis is in agreement with experimental works (based upon 
electrophoresis shift mobility assays) that demonstrated that Box A and Box B have 
different affinity towards some DNA forms like supercoiled and 4W J DNA (Box B can 
bind with equal extent to the two forms, whereas Box A -4W J DNA complex is more
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stable) (Poheler et al, 1997). Moreover, the chemical difference between the two binding 
sites could at least partially explain the different chemoattractant activity of Box A and 
Box B (Degryse et al., 2001) and, in the present work, the different behavior of Box A 
and Box B when complexed with low solubility ligand like CBNX.
In Chapter 4 a different strategy, with respect to docking, based on ab initio 
refinement of the standard force fields charges has been used to determine the structure 
of the complex formed by CBNX and Box A. The choice was twofold: i) CBNX lacks 
glicosidic moieties, that are very difficult to handle with quantum mechanics tools; ii) 
CBNX induced Box B precipitation even at low molar ratio, impairing the collection of 
structurally relevant information about this complex. This lead us to adopt for Box A-GL 
and for Box B-GL complexes the HADDOCK based strategy described before. However, 
QRFF based structure determination can be viewed as a valid tool for drug discovery 
(Ferrara et al., 2006) and for almost blind structure determination starting from a few 
experimental data. QRFF based method moves from first physical principles with the 
only help of chemical shift mapping results for positioning the ligand in the correct 
protein site, then allows system evolution towards minimum energy states using classical 
schemes. HADDOCK instead makes use of all the experimental data for generating the 
structure, adopting an energy minimization procedure that is very similar to standard 
NMR based structure determination. There is a good agreement between the QRFF and 
the HADDOCK determined structure of Box A-ligand complexes (FIG.5.3a) for what 
concerns the overall ligand orientation, although the two complexes cannot be directly 
compared. In both cases an interaction between the sidechain of Ser38 and a carboxyl 
group of GL/CBNX has been predicted (Fig. 5.3b), as expected for similar ligand in the 
same binding site of a protein, and the orientation of the two ligands is similar with 
respect to the overall position of the triterpenic moiety of GL and CBNX. These findings 
suggest that QRFF based methodology is a valid tool for the determination of structures 
in a drug discovery process and for the screening of many ligands (e.g., a ligands 
library). Our calculations indicate that this ab initio methodology, even starting from few 
experimental data, can lead to reliable results
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Fig. 5.3 B inding m odes o f  GL (red) and C B N X  (yellow) to Box A according to H A D D O C K  and Q RFF 
based strategies respectively, a. O verview  o f the binding b. Interaction betw een the ligand and the 
sidechain o f Ser38.
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Despite the goodness of the results obtained and the exiguous ^ experimental data used, 
the QRFF methodology is computationally expensive and it can only be applied with 
success and usefully if supported by a massive parallel computing frame. The 
HADDOCK based strategy, on the other side, has the disadvantage that a quite large 
amount of experimental data must be provided for getting good convergence in finding 
the solution to the problem of protein-ligand structure determination bypassing the NOE 
data collection: however, the very simple implementation of the software and the high 
number of structures that can be generated in a small amount of computing time make 
this approach suitable for getting a reliable and fast model of the complex under 
investigation.
5.6 Biological relevance of HMGB1-GL/CBNX interaction and future perspectives
The chemotactic and mitogenic properties of HMGB1 depend on its interaction with the 
receptor of advanced glycation end products (RAGE) (Palumbo et al 2004), even if the 
real nature of this interaction still remains controversial (Bierhaus et al., 2006). It is 
interesting to note that the RAGE binding surface on HMGB1 is represented by the 
stretch of basic amino acids between Box B and the acidic tail (Palumbo et al. 2004), and 
does not correspond to the surfaces engaged by GL. Moreover, the IC50 for the 
inhibition of HMGB 1-induced chemotaxis by GL is 50 pM for fibroblasts (see 
Introduction, Preliminary Data subsection, Fig.1.12 and 1.13), whereas the dissociation 
constant for GL and HMGB 1 is around 100-150 pM. These results suggest that another 
surface molecule, possibly belonging to the integrin family as recently suggested 
(Chavakis et al. 2003), also takes part in the binding of HMGB1 to RAGE, and favors 
the binding of GL to HMGB 1 on the cell surface. Glycyrrhizin is known to interfere with 
llb-hydroxysteroid dehydrogenase type 2, leading to an enhanced mineralcorticoid 
effect of cortisol (Ploeger et al., 2001). However, we tested the effect of cortisol on cell 
migration induced by HMGB1 and fMLP, and found none (data not shown). This 
suggests that the effects on llb-hydroxysteroid dehydrogenase type 2 and cell migration 
are distinct and separate.
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The presented findings indicate that extracellular HMGB1 role in inflammation 
could in principle reveal a new way to address the problem of finding new and safest 
strategies for blocking inflammation processes. This new view of inflammation 
processes is very similar to the research performed on IL33 and its interactions with SR2 
receptors (Schmitz et al. 2005), that demonstrated that a new way of rethinking 
inflammation mechanisms and their inhibition is possible by identifying small inhibitors 
of these nuclear proteins that are released in the outer cell space and act as cytokines. 
The advantage of adopting an HMGB1-GL interaction based strategy relies on the fact 
that here a small molecule that binds directly HMGB 1 can be proposed as a possible 
candidate as an antiinflammatory drug {i.e., a lead compound). Moreover, GL has been 
extensively studied in the past and used in clinical trials, hence its biological pathways 
are quite well known and characterized and effects on humans are thoroughly 
documented.
Despite the known features of the chemical and biophysical determinants of the 
proinflammatory activity of HMGB 1 and the presented results about the role of GL and 
CBNX in inhibiting its cytokine activity in vitro, some questions are still open. Even if 
no pathological mutants of HMGB 1 are known up to date, the usage of mutants of the 
protein can be of great interest in elucidating the role of some residues in driving the 
interactions with ligands and in confirming the effective role of HMGB1-GL binding in 
modulating proliferation and migration. The first step towards this type of investigation 
could be the determination of a set of mutants that are both able to retain the correct 
folding of the HMGB1 Boxes and, at the same time, to alter or cancel the GL binding 
properties of the protein. This can be done with the help of techniques presented within 
the text (NMR, MD) or recently introduced ad hoc for trying to establish the energetics 
of proteins using simple empirical models (e.g., FoldX)(Guerois et al., 2002), and also 
with the help of other biophysical techniques like Differential Scanning Calorimetry 
(DSC) able to determine the stability of mutants. In principle, this first step would lead 
to a set of proteins (mutHMGBl) that could be ranked with respect to the ability of 
binding GL in solution as tested by means, for example, of fluorescence spectroscopy.
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The second step would be based on the migration and proliferation assays performed as 
described in the Introduction starting from the two “extremes” of the aforementioned 
ranking (i.e. the mutant with the lowest Kd and the one with the highest Kd or no binding 
at all), measuring the migration and proliferation of cells using mutHMGBl as 
chemoattractant and as proliferative agents and GL as inhibitor of proliferation and 
migration. These experiments could address the following questions: a. if the mutations 
(and the subsequent modification of HMGB1 exposed surface) are able to alter the 
chemoattractant properties of HMGB1; b. if the residues mutated are really modulating 
the antiinflammatory properties of HMGB1 with respect to a different GL binding 
affinity. The first step, incidentally, could also identify regions of the protein surface that 
could be in contact with the HMGB1 receptor(s): this issue can be also covered 
performing the proliferation and migration assays with mutants that retain the correct 
protein folding and do not alter the binding mode of GL, i.e. mutants of residues that are 
distant from the GL binding site.
A possible future development of the presented work on the side of the physical 
chemical issues covered during the thesis work is the setup of an in silico drug discovery 
project that moves from the results of the presented QRFF based calculations performed 
on CBNX towards a complete screening of a very small library (no more than 100 
compounds) of GL-like compounds in order to find reliable targets with a more suitable 
Kd (i.e., in the nanomolar or low micromolar range) for pharmaceutical purposes. Of 
course, such a process could only be realized adopting massive parallel computing 
technologies and developing large scripts that would allow an extended automation of 
the whole process, from the creation of QRFF charges to the MD simulation analysis. A 
complete calculation performed on last generation cores equipped with the fastest 
intercommunication systems would take* no more than 8-12 hours for each compound 
for a single HMGB1 Box (2 hours for QRFF charges optimization, 6-10 hours for 
explicit solvent MD calculations). This procedure is to some extent more
*This estimate has been done hypothesizing the usage of no more than 16 cores and 20 configurations for each 
compound, performing short ( ~ 500 ps -  1 ns) MD simulations on last generation machines.
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computationally and time demanding than other rougher but faster algorithm (rigid body 
docking, Perola et al. 2004): however, at this stage of the work no experimental 
information would be needed, and the resulting ligand-protein complex would be 
physically reliable. In this way a smaller subset of 4 or 5 candidates with the lowest 
protein-ligand interaction energy would be available: this would be and an excellent 
starting point for more classical (3/4/5D QSAR, see Lukacova et al., 2004; Lill, 2007) 
and faster massive screening of large libraries (1000-2000 compounds) of molecules 
whose chemical structure could be finely tuned on the results of the previous 
calculations.
This drug discovery process of course should be coupled with NMR based 
screening experiments like Water LOGSY (Dalvit et al., 2003) or Saturation Transfer 
Difference (Mayer et al., 1999) performed on the most promising compounds in order to 
identify a pool of good targets for biochemical experiments that could elucidate the role 
of HMGB1 in inflammatory processes and to cross validate in silico screening. 
Experimental efforts also should be dedicated, at the end of both the computational and 
the spectroscopic drug discovery process, to the determination of the effects of the new 
compounds identified on both proliferation and migration in order to assess the in vitro 
role of a decreased Kd. This can be easily performed using the same assays previously 
used to describe the antiinflammatory features of GL on the citokine activity of 
HMGB1. The new compunds could be, finally, tested by means of proliferation and 
migration assays as described, both with wtHMGBl and with the most biologically 
relevant mutants previously selected on the basis of GL based experiments.
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